The present disclosure pertains to medical devices, and methods for manufacturing and/or using medical devices. More particularly, the present disclosure pertains to an improved design for a medical device and/or a replacement heart valve.
A wide variety of intracorporeal medical devices have been developed for medical use, for example, intravascular use. Some of these devices include guidewires, catheters, medical device delivery systems (e.g., for stents, grafts, replacement valves, etc.), and the like. These devices are manufactured by any one of a variety of different manufacturing methods and may be used according to any one of a variety of methods. Of the known medical devices and methods, each has certain advantages and disadvantages. There is an ongoing need to provide alternative medical devices as well as alternative methods for manufacturing and using medical devices.
In a first aspect, a medical implant may comprise an expandable anchor member having a lumen extending through the expandable anchor member from an inflow end to an outflow end; a plurality of valve leaflets disposed within the lumen extending through the expandable anchor member; a seal member disposed adjacent an exterior of the expandable anchor member; and a porous material extending from the seal member to the plurality of valve leaflets.
In addition or alternatively, the seal member is disposed outside of the lumen extending through the expandable anchor member.
In addition or alternatively, at least a portion of the porous material is disposed within the lumen extending through the expandable anchor member.
In addition or alternatively, the seal member includes a reinforcing band disposed proximate the inflow end of the expandable anchor member.
In addition or alternatively, the porous material extends from the reinforcing band to the plurality of valve leaflets.
In addition or alternatively, the reinforcing band does not pass through interstices in the expandable anchor member.
In addition or alternatively, the porous material does not pass through interstices in the expandable anchor member.
In addition or alternatively, the porous material includes a polymeric coating.
In addition or alternatively, a medical implant may comprise an expandable anchor member having a lumen extending through the expandable anchor member from an inflow end to an outflow end; a plurality of valve leaflets disposed within the lumen extending is through the expandable anchor member; a seal member disposed adjacent an exterior of the expandable anchor member; and a fabric material extending from the seal member to the plurality of valve leaflets, the fabric material having a plurality of holes therethrough permitting fluid to flow between an inflow side of the plurality of valve leaflets and an outflow side of the plurality of valve leaflets without passing through the plurality of valve leaflets.
In addition or alternatively, at least one seal stitch secures the seal member to the fabric material.
In addition or alternatively, the at least one seal stitch includes at least one whip stitch.
In addition or alternatively, at least one leaflet stitch secures the fabric material to the plurality of valve leaflets.
In addition or alternatively, the at least one leaflet stitch includes at least one whip stitch.
In addition or alternatively, the at least one leaflet stitch includes a running stitch.
In addition or alternatively, the at least one leaflet stitch includes a double running stitch.
In addition or alternatively, a medical implant may comprise an expandable anchor member having a lumen extending through the expandable anchor member from an inflow end to an outflow end; a plurality of valve leaflets disposed within the lumen extending through the expandable anchor member; and a seal member disposed adjacent an exterior of the expandable anchor member and attached to the plurality of valve leaflets at the inflow end of the expandable anchor member. The plurality of valve leaflets may each include a thinned region disposed proximate the inflow end of the expandable anchor member.
In addition or alternatively, the thinned region includes a plurality of holes extending through the thinned region permitting fluid to flow between an inflow side of the plurality of valve leaflets and an outflow side of the plurality of valve leaflets without passing through a lumen defined by free edges of the plurality of leaflets.
In addition or alternatively, the plurality of holes has a variable size.
In addition or alternatively, the plurality of holes decreases in size in a direction is from the inflow end of the expandable anchor member toward the outflow end of the expandable anchor member.
In addition or alternatively, the thinned region does not pass through interstices in the expandable anchor member.
The above summary of some embodiments, aspects, and/or examples is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The Figures, and Detailed Description, which follow, more particularly exemplify these embodiments.
The disclosure may be more completely understood in consideration of the following detailed description in connection with the accompanying drawings, in which:
While aspects of the disclosure are amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the disclosure to the particular embodiments described. On the contrary, is the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.
The following description should be read with reference to the drawings, which are not necessarily to scale, wherein like reference numerals indicate like elements throughout the several views. The detailed description and drawings are intended to illustrate but not limit the claimed invention. Those skilled in the art will recognize that the various elements described and/or shown may be arranged in various combinations and configurations without departing from the scope of the disclosure. The detailed description and drawings illustrate example embodiments of the claimed invention.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about”, in the context of numeric values, generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In many instances, the term “about” may include numbers that are rounded to the nearest significant figure. Other uses of the term “about” (e.g., in a context other than numeric values) may be assumed to have their ordinary and customary definition(s), as understood from and consistent with the context of the specification, unless otherwise specified.
The recitation of numerical ranges by endpoints includes all numbers within that range, including the endpoints (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
Although some suitable dimensions, ranges, and/or values pertaining to various components, features and/or specifications are disclosed, one of skill in the art, incited by the present disclosure, would understand desired dimensions, ranges, and/or values may deviate from those expressly disclosed.
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. It is to be noted that in order to facilitate understanding, certain features of the disclosure may be described in the singular, even though those features may be plural or recurring within the disclosed embodiment(s). Each instance of the features may include and/or be encompassed by the singular disclosure(s), unless expressly stated to the contrary. For simplicity and clarity purposes, not all elements of the disclosed invention are necessarily shown in each figure or discussed in detail below. However, it will be understood that the following discussion may apply equally to any and/or all of the components for which there are more than one, unless explicitly stated to the contrary. Additionally, not all instances of some elements or features may be shown in each figure for clarity.
Relative terms such as “proximal”, “distal”, “advance”, “retract”, variants thereof, and the like, may be generally considered with respect to the positioning, direction, and/or operation of various elements relative to a user/operator/manipulator of the device, wherein “proximal” and “retract” indicate or refer to closer to or toward the user and “distal” and “advance” indicate or refer to farther from or away from the user. In some instances, the terms “proximal” and “distal” may be arbitrarily assigned in an effort to facilitate understanding of the disclosure, and such instances will be readily apparent to the skilled artisan. Other relative terms, such as “upstream”, “downstream”, “inflow”, and “outflow” refer to a direction of fluid flow within a lumen, such as a body lumen, a blood vessel, or within a device. Still other relative terms, such as “axial”, “circumferential”, “longitudinal”, “lateral”, “radial”, etc. and/or variants thereof generally refer to direction and/or orientation relative to a central longitudinal axis of the disclosed structure or device.
The term “extent” may be understood to mean a greatest measurement of a stated or identified dimension, unless the extent or dimension in question is preceded by or identified as a “minimum”, which may be understood to mean a smallest measurement of the stated or identified dimension. For example, “outer extent” may be understood to mean an outer dimension, “radial extent” may be understood to mean a radial dimension, “longitudinal extent” may be understood to mean a longitudinal dimension, etc. Each instance of an “extent” may be different (e.g., axial, longitudinal, lateral, radial, circumferential, etc.) and will be apparent to the skilled person from the context of the individual usage. Generally, an “extent” may be considered a greatest possible dimension measured according to the intended usage, while a “minimum extent” may be considered is a smallest possible dimension measured according to the intended usage. In some instances, an “extent” may generally be measured orthogonally within a plane and/or cross-section, but may be, as will be apparent from the particular context, measured differently—such as, but not limited to, angularly, radially, circumferentially (e.g., along an arc), etc.
The terms “monolithic” and “unitary” shall generally refer to an element or elements made from or consisting of a single structure or base unit/element. A monolithic and/or unitary element shall exclude structure and/or features made by assembling or otherwise joining multiple discrete structures or elements together.
It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment(s) described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it would be within the knowledge of one skilled in the art to effect the particular feature, structure, or characteristic in connection with other embodiments, whether or not explicitly described, unless clearly stated to the contrary. That is, the various individual elements described below, even if not explicitly shown in a particular combination, are nevertheless contemplated as being combinable or arrangeable with each other to form other additional embodiments or to complement and/or enrich the described embodiment(s), as would be understood by one of ordinary skill in the art.
For the purpose of clarity, certain identifying numerical nomenclature (e.g., first, second, third, fourth, etc.) may be used throughout the description and/or claims to name and/or differentiate between various described and/or claimed features. It is to be understood that the numerical nomenclature is not intended to be limiting and is exemplary only. In some embodiments, alterations of and deviations from previously-used numerical nomenclature may be made in the interest of brevity and clarity. That is, a feature identified as a “first” element may later be referred to as a “second” element, a “third” element, etc. or may be omitted entirely, and/or a different feature may be referred to as the “first” element. The meaning and/or designation in each instance will be apparent to the skilled practitioner.
Diseases and/or medical conditions that impact the cardiovascular system are prevalent throughout the world. Traditionally, treatment of the cardiovascular system was often conducted by directly accessing the impacted part of the system. For example, treatment of a blockage in one or more of the coronary arteries was traditionally treated using coronary artery bypass surgery. As can be readily appreciated, such therapies are rather invasive to the patient and require significant recovery times and/or treatments. More recently, less invasive therapies have been developed, for example, where a blocked coronary artery could be accessed and treated via a percutaneous catheter (e.g., angioplasty). Such therapies have gained wide acceptance among patients and clinicians.
Some relatively common medical conditions may include or be the result of inefficiency, ineffectiveness, or complete failure of one or more of the valves within the heart. For example, failure of the aortic valve or the mitral valve can have a serious effect on a human and could lead to a serious health condition and/or death if not dealt with properly. Treatment of defective heart valves poses other challenges in that the treatment often requires the repair or outright replacement of the defective heart valve. Such therapies may be highly invasive to the patient. Disclosed herein is a medical device system that may be used for delivering a medical implant to a portion of the cardiovascular system in order to diagnose, treat, and/or repair the system. At least some of the medical implants and/or systems disclosed herein may be used to deliver and implant a replacement heart valve implant (e.g., a replacement aortic valve, replacement mitral valve, etc.). In addition, the medical device system may deliver the replacement heart valve implant percutaneously and, thus, may be much less invasive to the patient. The device and/or system disclosed herein may also provide other desirable features and/or benefits as described below.
The figures illustrate selected components and/or arrangements of a medical device system 10. It should be noted that in any given figure, some features of the medical device system 10 may not be shown, or may be shown schematically, for simplicity. Additional details regarding some of the components of the medical device system 10 may be illustrated in other figures in greater detail. A medical device system 10 may be used to deliver and/or deploy a variety of medical devices to a number of locations within the anatomy. In at least some embodiments, the medical device system 10 may include a replacement heart valve delivery system (e.g., a replacement aortic valve delivery system) that can be used for percutaneous delivery of a replacement heart valve. This, however, is not intended to be limiting as the medical device system 10 may also be used for other interventions including mitral valve replacement, valve repair, valvuloplasty, and the like, or other similar interventions.
The medical device system 10, as seen in
In use, the medical device system 10 may be advanced percutaneously through the is vasculature to a position adjacent to an area of interest or a target location. For example, the medical device system 10 may be advanced through the vasculature and across the aortic arch to a position adjacent to a defective aortic valve. Alternative approaches to treat a defective aortic valve and/or other heart valve(s) are also contemplated with the medical device system 10. During delivery, the medical implant 16 may be generally disposed in an elongated and low profile “delivery” configuration within the outer sheath 12 coupled to and/or distal of the inner catheter 14, as seen in
In at least some embodiments, the medical implant 16 may be disposed in an “everted” configuration or a partially-everted configuration while disposed within the lumen of the outer sheath 12 and/or immediately upon exposure after retracting the outer sheath 12. In some embodiments, the medical implant 16 may be everted in the “delivery” configuration. The “everted” configuration may involve at least a portion of the valve leaflets (discussed below) of the medical implant 16 being disposed outside of the expandable anchor member (discussed below) of the medical implant 16 during delivery, thereby permitting a smaller radial profile of the medical implant 16 and the use of a smaller overall profile of the outer sheath 12 and/or the medical device system 10. In some embodiments, the “delivery” configuration and the “everted” configuration may be is substantially similar and/or may be used interchangeably herein.
In some embodiments, the inner catheter 14 may be a tubular structure having one or more lumens extending therethrough. For example, in some embodiments, the inner catheter 14 may include one or more of a first lumen, a second lumen, a third lumen, and a fourth lumen. Other configurations are also contemplated. In some embodiments, the one or more lumens may extend along an entire length of the inner catheter 14. Other embodiments are contemplated, however, wherein one or more of the one or more lumens extend along only a portion of the length of the inner catheter 14. In some embodiments, a coupler assembly may be attached to the inner catheter 14 at and/or proximate a distal end of the inner catheter 14. In some embodiments, the coupler assembly may releasably couple the medical implant 16 to the inner catheter 14.
In some embodiments, the medical device system 10 may include at least one actuator element (not shown) releasably connecting the medical implant to the handle 18. For example, the at least one actuator element may extend from the handle 18 to the medical implant 16, the medical implant being disposed at a distal end of the lumen of the outer sheath 12. The at least one actuator element may extend distally from the inner catheter 14 to the medical implant 16. In some embodiments, the at least one actuator element may be slidably disposed within and/or may extend slidably through the inner catheter 14. For example, the at least one actuator element may be slidably disposed within one or more of the lumens of the inner catheter 14, and may be used to actuate (i.e., translate axially or longitudinally, and/or expand) the medical implant 16 between the “delivery” configuration, the “deployed” configuration, and/or the “released” configuration. In some embodiments, the at least one actuator element may include a plurality of actuator elements, two actuator elements, three actuator elements, four actuator elements, or another suitable or desired number of actuator elements.
For the purpose of discussion only, the medical device system 10 and/or the medical implant 16 of
It is to be noted that in order to facilitate understanding, certain features of the disclosure may be described in the singular, even though those features may be plural or recurring within the disclosed embodiment(s). Each instance of the features may include and/or be encompassed by the singular disclosure(s), unless expressly stated to the contrary. For example, a reference to “the actuator element”, “the leaflets”, “the lumen”, or other features may be equally referred to all instances and quantities beyond one of said feature. As such, it will be understood that the following discussion may apply equally to any and/or all of the components for which there are more than one within the medical implant 16 (i.e., the at least one actuator element, the plurality of leaflets, etc.) and/or the medical device system 10, unless explicitly stated to the contrary. Additionally, not all instances of some elements or features may be shown in each figure for clarity.
In some embodiments, the medical implant 16 may include a plurality of locking elements 76 attached to the expandable anchor member 70, the plurality of locking elements 76 being configured to lock the expandable anchor member 70 in the “deployed” and/or “released” configuration(s). In some embodiments, the at least one actuator element may be configured to actuate the expandable anchor member 70 and/or the medical implant 16 between the “delivery” configuration and the “deployed” configuration and/or the “released” configuration.
In some embodiments, the plurality of locking elements 76 may each comprise an axially movable post member, for example at the commissure portions of the valve leaflets 68 (the post member may sometimes be referred to as a portion of a commissure post, which may serve to secure the valve leaflets 68, or the post member may be connected and/or attached to a commissure post), and a buckle member or other receiving element configured to slidably receive the post member therein to engage with the buckle member and thereafter lock the expandable anchor member 70 and/or the medical implant 16 in the “deployed” and/or the “released” configuration(s). In other words, in at least some embodiments, a medical implant 16 may include a plurality of post members and a corresponding plurality of buckle members. Other configurations and correspondences are also contemplated. Some suitable but non-limiting materials for the plurality of locking elements 76, the buckle member, and/or the post member, for example metallic materials or polymeric materials, are described below.
In some embodiments, the plurality of valve leaflets 68 may be secured to the expandable anchor member 70 at, adjacent to, and/or using (at least in part) corresponding post members. In some embodiments, the plurality of valve leaflets 68 may also be secured to the inflow end 24 of the expandable anchor member 70. In some embodiments, the plurality of valve leaflets 68 may be coupled and/or secured (i.e., to the post member, to the expandable anchor member 70, and/or back to themselves) using one or more sutures, threads, wires, filaments, adhesives, bonding agents, or other suitable elements and/or combinations thereof. In some embodiments, the plurality of valve leaflets 68 may be directly attached to the expandable anchor member 70. In some embodiments, the plurality of valve leaflets 68 may not be directly attached to the expandable anchor member 70.
In some embodiments, the post members and/or the commissure posts may be secured and/or attached to the expandable anchor member 70 (e.g., along the interior of the expandable anchor member) with sutures, tethers, adhesives, or other suitable elements. In some embodiments, the commissure post and/or the post member may include one or more holes or other features provided to aid in securing and/or attaching the commissure post and/or the post member to the expandable anchor member 70. Positioned adjacent to (e.g., aligned with) the plurality of post members is a corresponding plurality of buckle members, which may be secured and/or fixedly attached to the expandable anchor member 70 (e.g., along the interior of the expandable anchor member 70) with sutures, adhesives, or other suitable mechanisms. In some embodiments, the post member may be axially translatable relative to the buckle member generally parallel to the central longitudinal axis of the expandable anchor member 70 when the post member is at least partially disposed within and/or engaged with the buckle member.
In some embodiments, one buckle member may be fixedly attached to the expandable anchor member 70 adjacent to each of the post members. Accordingly, in some embodiments, the expandable anchor member 70 may have a total of three buckle members and three post members attached thereto. Similarly, one actuator element may be associated with each post member and buckle member, for a total of three actuator elements in the given example(s). Other embodiments are contemplated where fewer or more buckle members, post members, and/or actuator elements may be utilized.
In some embodiments, a seal member 30 may be circumferentially disposed on, about, and/or adjacent the exterior of the expandable anchor member 70, as seen in
In some embodiments, the seal member 30 may include a plurality of grommets 38.
The plurality of grommets 38 may be attached to, bonded to, and/or at least partially embedded in the seal member 30. The plurality of grommets 38 may act as reinforcement points for attachment of the seal member 30 to the expandable anchor member 70 using a plurality of lashing sutures 46. In some embodiments, the plurality of lashing sutures 46 may extend through the plurality of grommets 38. In some embodiments, the plurality of lashing sutures 46 may attach the seal member 30 to the expandable anchor member 70 at non-consecutive intersections of the struts or filaments.
In some embodiments, the seal member 30 may include one or more layers of polymeric material. Some suitable polymeric materials may include, but are not necessarily limited to, polycarbonate, polyurethane, polyamide, polyether block amide, polyethylene, polyethylene terephthalate, polypropylene, polyvinylchloride, polytetrafluoroethylene, polysulfone, and copolymers, blends, mixtures or combinations thereof. Other suitable polymeric materials are also contemplated, some of which are discussed below.
In some embodiments, the modulus of elasticity may vary and/or be different from layer to layer. In other embodiments, the elongation to break may vary and/or be different from layer to layer. In some embodiments, the seal member 30 may also include a reinforcement, a reinforcing layer, and/or one or more reinforcing members added to the polymeric material prior to curing. The reinforcement, the reinforcing layer, and/or the one or more reinforcing members may comprise a woven or nonwoven fabric and may be positioned within or between the various layers. In some embodiments, the reinforcement, the reinforcing layer, and/or the one or more reinforcing members may be positioned on a radially innermost surface or radially outermost surface of the seal member 30. In some embodiments, the reinforcement, the reinforcing layer, and/or the one or more reinforcing members may be generally aligned. In some embodiments, the reinforcement, the reinforcing layer, and/or the one or more reinforcing members may be randomly oriented and/or disposed on the seal member 30. In some embodiments, at least a portion of the seal member 30 may be formed from a fabric material having a polymeric coating 33. In at least some embodiments, the seal member 30 may be impermeable to fluids and/or blood.
In some embodiments, the seal member 30 may include a reinforcing band 32 coupled to the seal member 30 and/or disposed proximate the inflow end 24 of the expandable anchor member 70. In some embodiments, the reinforcing band 32 may be integrally formed with, incorporated into, adhered to, and/or at least partially embedded within the seal member 30. In some embodiments, the reinforcing band 32 may be formed from a woven or nonwoven fabric material, a textile, or other thin flexible material. In some embodiments, the reinforcing band 32 may be the at least a portion of the seal member 30 formed from the fabric material having the polymeric coating 33. The reinforcing band 32 may provide tear resistance in the vicinity of sutures, filaments, or other attachment elements associated with components or aspects of the medical implant 16. In some embodiments, the reinforcing band 32 may have a longitudinal length measured parallel to the central longitudinal axis of about 1.5 millimeters, about 1.8 millimeters, about 2.0 millimeters, about 2.2 millimeters, about 2.5 millimeters, about 3 millimeters, etc.
In some embodiments, at least one seal stitch 40 may attach the inflow end of the seal member 30 and/or the reinforcing band 32 to the inflow end 24 of the expandable anchor member 70. In some embodiments, the at least one seal stitch 40 may include at least one whip stitch. A whip stitch may sometimes be referred to and/or interchanged with a helical stitch. In some embodiments, the at least one seal stitch 40 may form one or more first helical spirals oriented in a first direction about the inflow end 24 of the expandable anchor member 70.
In some embodiments, the medical implant 16 may include a porous material 36 extending from the seal member 30 and/or the reinforcing band 32 to the plurality of valve leaflets 68, as seen in
At least a portion of the porous material 36, the blood-permeable material, and/or the fabric material is disposed within the lumen extending through the expandable anchor member 70. In some embodiments, the porous material 36, the fabric material, and/or the blood-permeable material may have about 30% open area, about 35% open area, about 38% open area, about 40% open area, about 45% open area, etc. In some embodiments, the porous material 36, the fabric material, and/or the blood-permeable material may have a longitudinal length measured parallel to the central longitudinal axis of about 3.0 millimeters, about 3.5 millimeters, about 3.8 millimeters, about 4.0 millimeters, about 4.2 millimeters, about 4.5 millimeters, about 5 millimeters, etc.
In some embodiments, the polymeric coating 33 of the seal member 30 and/or the reinforcing band 32 is thicker than the polymeric coating 37 of the porous material 36, the fabric material, and/or the blood-permeable material. For example, the polymeric coating 33 of the seal member 30 and/or the reinforcing band 32 may close, plug, and/or seal off any holes, apertures, pores, and/or openings extending therethrough, while the plurality of holes 34, apertures, pores, and/or openings extending through the porous material 36, the fabric material, and/or the blood-permeable material may be at least partially unobstructed by the polymeric coating 37 thereon. In some embodiments, the polymeric coating 33 of the seal member 30 and/or the reinforcing band 32 may be at least about 30 microns thick, about 40 microns thick, about 50 microns thick, about 55 microns thick, about 60 microns thick, or another suitable thickness. In some embodiments, the polymeric coating 37 of the porous material 36, the fabric material, and/or the blood-permeable material may be less than 10 microns thick, about 5 microns thick, about 3 microns thick, about 2 microns thick, about 1 micron thick, or another suitable thickness.
In some embodiments, the at least one seal stitch 40 may attach the reinforcing band 32 and/or the inflow end of the reinforcing band 32 to an inflow end of the porous material 36 (e.g., the fabric material, etc.) adjacent the inflow end 24 of the expandable anchor member 70. In some embodiments, one or more inflow lashing sutures 44 may secure the at least one seal stitch 40, the inflow end of the porous material 36, the inflow end of the seal member 30, and/or the reinforcing band 32 to the expandable anchor member 70 at, proximate, and/or to the inflow end 24 of the expandable anchor member 70. In at least some embodiments, the one or more inflow lashing sutures 44 may attach the at least one seal stitch 40, the inflow end of the porous material 36, the inflow end of the seal member 30, and/or the reinforcing band 32 to the strut(s), filament(s), and/or intersection(s) thereof of the expandable anchor member 70 disposed and/or positioned closest to the inflow end 24 of the expandable anchor member 70.
In some embodiments, the one or more inflow lashing sutures 44 may directly attach the at least one seal stitch 40 to the inflow end 24 of the expandable anchor member is 70. In some embodiments, the one or more inflow lashing sutures 44 may be interwoven with the at least one seal stitch 40 and/or a plurality of windings of the at least one seal stitch 40 to form a suture lattice. In some embodiments, at least a portion of the one or more inflow lashing sutures 44 may be looped through an interior of one or more of the plurality of windings of the at least one seal stitch 40 to form the suture lattice. In some embodiments, the one or more inflow lashing sutures 44 may form one or more second helical spirals oriented in a second direction about the inflow end 24 of the expandable anchor member 70. In some embodiments, the one or more inflow lashing sutures 44 may form one or more second helical spirals oriented in a second direction about the inflow end 24 of the expandable anchor member 70. In some embodiments, the first direction may be opposite the second direction.
As may be seen in
In some embodiments, at least one leaflet stitch 42 may secure the porous material 36, the blood-permeable material, and/or the fabric material to the plurality of valve leaflets 68. In some embodiments, the at least one leaflet stitch 42 may include at least one whip stitch, as shown in
In the partial cutaway view of
In some embodiments, the porous material 36, the blood-permeable material, and/or the fabric material may have a sinusoidal or wave-like longitudinal length and/or profile. In this configuration, the plurality of valve leaflets 68 may also have a sinusoidal or wave-like inflow end corresponding to the porous material 36, the blood-permeable material, and/or the fabric material.
In the partial cutaway view of
Adjacent leaflets of the plurality of valve leaflets 68 may be secured and/or attached together at a valve commissure at one of the plurality of locking elements 76. The adjacent leaflets of the plurality of valve leaflets 68 may be attached to the post member of the locking element 76 by one or more commissure sutures. As may be seen in
In an alternative configuration, the medical implant 16 may include a thinned region 69 of the plurality of valve leaflets 68 (e.g., leaflet tissue) extending to and/or attached directly to the seal member 30 and/or the reinforcing band 32, as seen in
In some embodiments, the thinned region 69 of the plurality of valve leaflets 68 may be formed by applying pressure to a portion of the plurality of valve leaflets 68 using a press or other means. In some embodiments, a portion of each of the plurality of valve leaflets 68 may be compressed to reduce a thickness of the portion of each of the plurality of valve leaflets 68 by about 30%, about 40%, about 50%, about 60%, about 70% or more. In some embodiments, the thinned region 69 may have a thickness that is approximately ⅓ of the thickness of an un-thinned region of the plurality of valve leaflets 68. In one example, the plurality of valve leaflets may have a thickness of about 0.381 millimeters (about 0.0015 inches) and the thinned region 69 may have a thickness of about 0.127 millimeters (about 0.005 inches). Other configurations and/or thicknesses are also contemplated.
At least a portion of the thinned region 69 including the plurality of holes 67 is disposed within the lumen extending through the expandable anchor member 70. In some embodiments, the thinned region 69 including the plurality of holes 67 may have about 30% open area, about 35% open area, about 38% open area, about 40% open area, about 45% open area, etc. In some embodiments, the thinned region 69 including the plurality of holes 67 may have a longitudinal length measured parallel to the central longitudinal axis of about 3.0 millimeters, about 3.5 millimeters, about 3.8 millimeters, about 4.0 millimeters, about 4.2 millimeters, about 4.5 millimeters, about 5 millimeters, etc.
In some embodiments, the at least one seal stitch 40 may attach the reinforcing band 32 and/or the inflow end of the reinforcing band 32 to an inflow end of the thinned region 69 including the plurality of holes 67 and/or the plurality of valve leaflets 68 adjacent the inflow end of the expandable anchor member 70. In some embodiments, one or more is inflow lashing sutures 44 may secure the at least one seal stitch 40, the inflow end of the thinned region 69 including the plurality of holes 67, the inflow end of the seal member 30, and/or the reinforcing band 32 to the expandable anchor member 70 at, proximate, and/or to the inflow end of the expandable anchor member 70. In at least some embodiments, the one or more inflow lashing sutures 44 may attach the at least one seal stitch 40, the inflow end of the thinned region 69 including the plurality of holes 67, the inflow end of the seal member 30, and/or the reinforcing band 32 to the strut(s), filament(s), and/or intersection(s) thereof of the expandable anchor member 70 disposed and/or positioned closest to the inflow end of the expandable anchor member 70.
In some embodiments, the one or more inflow lashing sutures 44 may directly attach the at least one seal stitch 40 to the inflow end of the expandable anchor member 70.
In some embodiments, the one or more inflow lashing sutures 44 may be interwoven with the at least one seal stitch 40 and/or a plurality of windings of the at least one seal stitch 40 to form a suture lattice. In some embodiments, at least a portion of the one or more inflow lashing sutures 44 may be looped through an interior of one or more of the plurality of windings of the at least one seal stitch 40 to form the suture lattice. In some embodiments, the one or more inflow lashing sutures 44 may form one or more second helical spirals oriented in a second direction about the inflow end of the expandable anchor member 70. In some embodiments, the one or more inflow lashing sutures 44 may form one or more second helical spirals oriented in a second direction about the inflow end of the expandable anchor member 70. In some embodiments, the first direction may be opposite the second direction.
As may be seen in
In another alternative configuration, the seal member 30 and/or the reinforcing band 32 may extend into the lumen of the expandable anchor member 70 and attach directly to the plurality of valve leaflets 68, as seen in
At least a portion of the seal member 30 and/or the reinforcing band 32 including the plurality of holes 31 is disposed within the lumen extending through the expandable anchor member 70. In some embodiments, the seal member 30 and/or the reinforcing band 32 including the plurality of holes 31 may have about 30% open area, about 35% open area, about 38% open area, about 40% open area, about 45% open area, etc. In some embodiments, a portion of the seal member 30 and/or the reinforcing band 32 including the plurality of holes 31 may have a longitudinal length measured parallel to the central longitudinal axis of about 3.0 millimeters, about 3.5 millimeters, about 3.8 millimeters, about 4.0 millimeters, about 4.2 millimeters, about 4.5 millimeters, about 5 millimeters, etc.
In some embodiments, the polymeric coating 33 of the seal member 30 and/or the reinforcing band 32 outside of the lumen of the expandable anchor member 70 is thicker than the polymeric coating 37 disposed within the lumen of the expandable anchor member 70. For example, the polymeric coating 33 of the seal member 30 and/or the reinforcing band 32 may close, plug, and/or seal off any holes, apertures, pores, and/or openings extending therethrough outside of the lumen of the expandable anchor member 70, while the plurality of holes 31 extending through the seal member 30 and/or the reinforcing band is 32 within the lumen of the expandable anchor member 70 may be at least partially unobstructed by the polymeric coating 37 thereon. In some embodiments, the polymeric coating 33 of the seal member 30 and/or the reinforcing band 32 may be at least about 30 microns thick, about 40 microns thick, about 50 microns thick, about 55 microns thick, about 60 microns thick, or another suitable thickness. In some embodiments, the polymeric coating 37 may be less than 10 microns thick, about 5 microns thick, about 3 microns thick, about 2 microns thick, about 1 micron thick, or another suitable thickness. For example, the entire seal member 30 and/or the entire reinforcing band 32 may comprise a polymeric coating thereon. In some embodiments, the polymeric coating may have different and/or varying thicknesses depending on where the polymeric coating is disposed on the seal member 30 and/or the reinforcing band 32. As noted herein, it is desirable for the plurality of holes 31 to remain at least partially unobstructed to facilitate fluid passage therethrough. The plurality of holes 31 is disposed between the inflow end of the expandable anchor member 70 and the inflow end of the plurality of valve leaflets 68, within the lumen of the expandable anchor member 70.
Similar to the configuration described above with respect to
In some embodiments, the at least one seal stitch 40 may attach the seal member 30 and/or the reinforcing band 32 to the inflow end of the expandable anchor member 70 such is that the plurality of holes 31 is disposed within the lumen of the expandable anchor member 70. In some embodiments, the at least one seal stitch 40 may be at least one whip stitch or at least one helical stitch. In at least some embodiments, the at least one seal stitch 40 may attach the seal member 30 and/or the reinforcing band 32 to the strut(s), filament(s), and/or intersection(s) thereof of the expandable anchor member 70 disposed and/or positioned closest to the inflow end of the expandable anchor member 70.
As may be seen in
As a result of the aforementioned construction, the medical implant 16 may be is substantially sealed against fluid and/or blood flow around the exterior of the expandable anchor member 70 when positioned within the target site (e.g., the native valve) in the “deployed” configuration and/or the “released” configuration. The plurality of holes 34 of the porous material 36, the blood-permeable material, and/or the fabric material extending from the seal member 30 and/or the reinforcing band 32 to the plurality of valve leaflets 68, the plurality of holes 67 in the thinned region 69 of the plurality of valve leaflets 68, and/or the plurality of holes 31 in the seal member 30 and/or the reinforcing band 32 may provide one or more benefits to the function of the medical implant 16. For example, a pre-selected amount of fluid and/or blood may be permitted to flow through the plurality of holes 34, 67, 31. The pre-selected amount of fluid and/or blood may be selected to meet desired performance, anatomical, and/or regulatory requirements.
During the diastolic phase of the heartbeat, fluid and/or blood flow through the plurality of holes 34 of the porous material 36, the blood-permeable material, and/or the fabric material extending from the seal member 30 and/or the reinforcing band 32 to the plurality of valve leaflets 68, the plurality of holes 67 in the thinned region 69 of the plurality of valve leaflets 68, and/or the plurality of holes 31 in the seal member 30 and/or the reinforcing band 32 may serve to help “wash out” any fluid or blood that may be starting to stagnate behind the plurality of valve leaflets 68 in the cusps thereof (e.g., between the outflow side of the plurality of valve leaflets and the seal member 30 and/or the native valve annulus). This may help to prevent thrombus formation and/or release, which may have detrimental effects in/on other parts of the patient's anatomy. In some embodiments, the plurality of holes 34 of the porous material 36, the blood-permeable material, and/or the fabric material extending from the seal member 30 and/or the reinforcing band 32 to the plurality of valve leaflets 68, the plurality of holes 67 in the thinned region 69 of the plurality of valve leaflets 68, and/or the plurality of holes 31 in the seal member 30 and/or the reinforcing band 32 may alternatively and/or additionally reduce peak mechanical loads and/or strains applied to the expandable anchor member 70 during coaptation of the plurality of valve leaflets 68, thereby causing a damping effect during coaptation of the plurality of valve leaflets 68. Reducing peak mechanical loads and/or strains applied to the expandable anchor member 70, and/or the damping effect, may reduce wear and/or increase longevity of the expandable anchor member 70.
In another example, the plurality of holes 34 of the porous material 36, the blood-permeable material, and/or the fabric material extending from the seal member 30 and/or the reinforcing band 32 to the plurality of valve leaflets 68, the plurality of holes 67 in the thinned region 69 of the plurality of valve leaflets 68, and/or the plurality of holes 31 in the seal member 30 and/or the reinforcing band 32 may increase the effective orifice area (EOA) of the medical implant 16 by improving the flexibility and/or “hinge effect” of the plurality of valve leaflets 68 at the inflow end thereof when compared to medical implants lacking this feature and/or having valve leaflets secured directly to the expandable anchor member. The effective orifice area may be defined as the cross-sectional area through the lumen of the expandable anchor member 70 less the cross-sectional area through the lumen of the expandable anchor member 70 occupied by the plurality of valve leaflets 68 (e.g., the cross-sectional area through/within the plurality of leaflets 68 that is open to fluid flow during systole). The plurality of holes 34 of the porous material 36, the blood-permeable material, and/or the fabric material extending from the seal member 30 and/or the reinforcing band 32 to the plurality of valve leaflets 68, the plurality of holes 67 in the thinned region 69 of the plurality of valve leaflets 68, and/or the plurality of holes 31 in the seal member 30 and/or the reinforcing band 32 may permit the plurality of valve leaflets 68 to open faster and with less effort during systole, thereby reducing a pressure drop due to flow dynamics and/or minimizing the pressure gradient between inflow end and outflow end, which increases the effective orifice area when the Gorlin pressure equation is applied:
The Gorlin equation states that the aortic valve area is equal to the flow through the aortic valve during ventricular systole divided by the systolic pressure gradient across the valve times a constant.
The materials that can be used for the various components of the medical device system 10 (and/or other systems disclosed herein) and the various elements thereof disclosed herein may include those commonly associated with medical devices. For simplicity purposes, the following discussion refers to the medical device system 10 and/or the medical implant 16. However, this is not intended to limit the devices and methods described herein, as the discussion may be applied to other elements, members, components, or devices disclosed herein, such as, but not limited to, the seal member 30, the reinforcing band 32, the polymeric coating 33, the porous material 36, the polymeric coating 37, the grommets 38, the sutures 40/42/44/46/77, the expandable anchor member 70, and/or elements or components thereof.
In some embodiments, the medical device system 10, the delivery system, and/or the medical implant 16, and/or components thereof, may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable material.
Some examples of suitable polymers may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN® available from DuPont), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), Marlex high-density polyethylene, Marlex low-density polyethylene, linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID® available from EMS American Grilon), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, polyurethane silicone copolymers (for example, ElastEon® from Aortech Biomaterials or ChronoSil® from AdvanSource Biomaterials), biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments the sheath can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6 percent LCP.
Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; platinum; palladium; gold; combinations thereof; or any other suitable material.
As alluded to herein, within the family of commercially available nickel-titanium or nitinol alloys, is a category designated “linear elastic” or “non-super-elastic” which, although may be similar in chemistry to conventional shape memory and super elastic varieties, may exhibit distinct and useful mechanical properties. Linear elastic and/or non-super-elastic nitinol may be distinguished from super elastic nitinol in that the linear elastic and/or non-super-elastic nitinol does not display a substantial “superelastic plateau” or “flag region” in its stress/strain curve like super elastic nitinol does. Instead, in the linear elastic and/or non-super-elastic nitinol, as recoverable strain increases, the stress continues to increase in a substantially linear, or a somewhat, but not necessarily entirely linear relationship until plastic deformation begins or at least in a relationship that is more linear than the super elastic plateau and/or flag region that may be seen with super elastic nitinol. Thus, for the purposes of this disclosure linear elastic and/or non-super-elastic nitinol may also be termed “substantially” linear elastic and/or non-super-elastic nitinol.
In some cases, linear elastic and/or non-super-elastic nitinol may also be is distinguishable from super elastic nitinol in that linear elastic and/or non-super-elastic nitinol may accept up to about 2-5% strain while remaining substantially elastic (e.g., before plastically deforming) whereas super elastic nitinol may accept up to about 8% strain before plastically deforming. Both of these materials can be distinguished from other linear elastic materials such as stainless steel (that can also be distinguished based on its composition), which may accept only about 0.2 to 0.44 percent strain before plastically deforming.
In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy is an alloy that does not show any martensite/austenite phase changes that are detectable by differential scanning calorimetry (DSC) and dynamic metal thermal analysis (DMTA) analysis over a large temperature range. For example, in some embodiments, there may be no martensite/austenite phase changes detectable by DSC and DMTA analysis in the range of about −60 degrees Celsius (° C.) to about 120° C. in the linear elastic and/or non-super-elastic nickel-titanium alloy. The mechanical bending properties of such material may therefore be generally inert to the effect of temperature over this very broad range of temperature. In some embodiments, the mechanical bending properties of the linear elastic and/or non-super-elastic nickel-titanium alloy at ambient or room temperature are substantially the same as the mechanical properties at body temperature, for example, in that they do not display a super-elastic plateau and/or flag region. In other words, across a broad temperature range, the linear elastic and/or non-super-elastic nickel-titanium alloy maintains its linear elastic and/or non-super-elastic characteristics and/or properties. In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy may be in the range of about 50 to about 60 weight percent nickel, with the remainder being essentially titanium. In some embodiments, the composition is in the range of about 54 to about 57 weight percent nickel. One example of a suitable nickel-titanium alloy is FHP-NT alloy commercially available from Furukawa Techno Material Co. of Kanagawa, Japan. Other suitable materials may include ULTANIUM™ (available from Neo-Metrics) and GUM METAL™ (available from Toyota). In some other embodiments, a superelastic alloy, for example a superelastic nitinol can be used to achieve desired properties.
In at least some embodiments, portions or all of the delivery system and/or the medical implant 16, and/or components thereof, may also be doped with, made of, or otherwise include a radiopaque material. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of the medical device system 10 in determining its location. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like. Additionally, other radiopaque marker bands and/or coils may also be incorporated into the design of the medical device system 10 to achieve the same result.
In some embodiments, a degree of Magnetic Resonance Imaging (MRI) compatibility is imparted into the medical device system 10 and/or the medical implant 16 and/or other elements disclosed herein. For example, the medical device system 10 and/or the medical implant 16, and/or components or portions thereof, may be made of a material that does not substantially distort the image and create substantial artifacts (i.e., gaps in the image). Certain ferromagnetic materials, for example, may not be suitable because they may create artifacts in an MRI image. The medical device system 10 and/or the medical implant 16, or portions thereof, may also be made from a material that the MRI machine can image. Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nitinol, and the like, and others.
In some embodiments, the medical device system 10 and/or the medical implant 16 and/or other elements disclosed herein may include a fabric material disposed over or within the structure. The fabric material may be composed of a biocompatible material, such a polymeric material or biomaterial, adapted to promote tissue ingrowth. In some embodiments, the fabric material may include a bioabsorbable material. Some examples of suitable fabric materials include, but are not limited to, polyethylene glycol (PEG), nylon, polytetrafluoroethylene (PTFE, ePTFE), a polyolefinic material such as a polyethylene, a polypropylene, polyester, polyurethane, and/or blends or combinations thereof.
In some embodiments, the medical device system 10 and/or the medical implant 16 and/or other elements disclosed herein may include and/or be formed from a textile material. Some examples of suitable textile materials may include synthetic yarns that may be flat, shaped, twisted, textured, pre-shrunk or un-shrunk. Synthetic biocompatible yarns suitable for use in the present invention include, but are not limited to, polyesters, including polyethylene terephthalate (PET) polyesters, polypropylenes, polyethylenes, polyurethanes, polyolefins, polyvinyl s, polymethylacetates, polyamides, naphthalene dicarboxylene derivatives, natural silk, and polytetrafluoroethylenes. Moreover, at least one of the synthetic yarns may be a metallic yarn or a glass or ceramic yarn or fiber. Useful metallic yarns include those yarns made from or containing stainless steel, platinum, gold, titanium, tantalum or a Ni—Co—Cr-based alloy. The yarns may further include carbon, glass or ceramic fibers. Desirably, the yarns are made from thermoplastic materials including, but not limited to, polyesters, polypropylenes, polyethylenes, polyurethanes, polynaphthalenes, polytetrafluoroethylenes, and the like. The yarns may be of the multifilament, monofilament, or spun-types. The type and denier of the yarn chosen may be selected in a manner which forms a biocompatible and implantable prosthesis and, more particularly, a vascular structure having desirable properties.
In some embodiments, the medical device system 10 and/or the medical implant 16 and/or other elements disclosed herein may include and/or be treated with a suitable therapeutic agent. Some examples of suitable therapeutic agents may include anti-thrombogenic agents (such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone)); anti-proliferative agents (such as enoxaparin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid); anti-inflammatory agents (such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine); antineoplastic/antiproliferative/anti-mitotic agents (such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors); anesthetic agents (such as lidocaine, bupivacaine, and ropivacaine); anti-coagulants (such as D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, anti-thrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors, and tick antiplatelet peptides); vascular cell growth promoters (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters); vascular cell growth inhibitors (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin); cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms.
It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the invention. This may include, to the extent that it is appropriate, the use of any of the features of one example embodiment being used in other embodiments. The invention's scope is, of course, defined in the language in which the appended claims are expressed.
This application claims the benefit of priority of U.S. Provisional Application No. 62/846,018 filed May 10, 2019, the entire disclosure of which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
15192 | Peale | Jun 1856 | A |
2682057 | Lord | Jun 1954 | A |
2701559 | Cooper | Feb 1955 | A |
2832078 | Williams | Apr 1958 | A |
3029819 | Starks | Apr 1962 | A |
3099016 | Lowell | Jul 1963 | A |
3113586 | Edmark | Dec 1963 | A |
3130418 | Head et al. | Apr 1964 | A |
3143742 | Cromie | Aug 1964 | A |
3221006 | Moore et al. | Nov 1965 | A |
3334629 | Cohn | Aug 1967 | A |
3365728 | Edwards et al. | Jan 1968 | A |
3367364 | Cruz et al. | Feb 1968 | A |
3409013 | Henry | Nov 1968 | A |
3445916 | Schulte | May 1969 | A |
3503079 | Smith | Mar 1970 | A |
3540431 | Mobin-Uddin | Nov 1970 | A |
3546711 | Bokros | Dec 1970 | A |
3548417 | Kischer et al. | Dec 1970 | A |
3551913 | Shiley et al. | Jan 1971 | A |
3570014 | Hancock | Mar 1971 | A |
3587115 | Shiley | Jun 1971 | A |
3592184 | Watkins et al. | Jul 1971 | A |
3628535 | Ostrowsky et al. | Dec 1971 | A |
3642004 | Osthagen et al. | Feb 1972 | A |
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3714671 | Goodenough et al. | Feb 1973 | A |
3725961 | Magovem et al. | Apr 1973 | A |
3755823 | Hancock | Sep 1973 | A |
3795246 | Sturgeon | Mar 1974 | A |
3839741 | Haller | Oct 1974 | A |
3868956 | Alfidi et al. | Mar 1975 | A |
3874388 | King et al. | Apr 1975 | A |
3983581 | Angell et al. | Oct 1976 | A |
3997923 | Possis | Dec 1976 | A |
4035849 | Angell et al. | Jul 1977 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4084268 | Ionescu et al. | Apr 1978 | A |
4106129 | Carpentier et al. | Aug 1978 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4233690 | Akins | Nov 1980 | A |
4265694 | Boretos et al. | May 1981 | A |
4291420 | Reul | Sep 1981 | A |
4297749 | Davis et al. | Nov 1981 | A |
4323358 | Lentz et al. | Apr 1982 | A |
4326306 | Poler | Apr 1982 | A |
4339831 | Johnson | Jul 1982 | A |
4340977 | Brownlee et al. | Jul 1982 | A |
4343048 | Ross et al. | Aug 1982 | A |
4345340 | Rosen | Aug 1982 | A |
4373216 | Klawitter | Feb 1983 | A |
4388735 | Ionescu et al. | Jun 1983 | A |
4406022 | Roy | Sep 1983 | A |
4423809 | Mazzocco | Jan 1984 | A |
4425908 | Simon | Jan 1984 | A |
4470157 | Love | Sep 1984 | A |
4473423 | Kolff | Sep 1984 | A |
4484365 | Murguet et al. | Nov 1984 | A |
4484579 | Meno et al. | Nov 1984 | A |
4490859 | Black et al. | Jan 1985 | A |
4501030 | Lane | Feb 1985 | A |
4510628 | Kolff | Apr 1985 | A |
4531943 | Tassel et al. | Jul 1985 | A |
4535483 | Klawitter et al. | Aug 1985 | A |
4574803 | Storz | Mar 1986 | A |
4580568 | Gianturco | Apr 1986 | A |
4592340 | Boyles | Jun 1986 | A |
4602911 | Ahmadi et al. | Jul 1986 | A |
4605407 | Black et al. | Aug 1986 | A |
4610688 | Silvestrini et al. | Sep 1986 | A |
4612011 | Kautzky | Sep 1986 | A |
4617932 | Kornberg | Oct 1986 | A |
4643732 | Pietsch et al. | Feb 1987 | A |
4647283 | Carpentier et al. | Mar 1987 | A |
4648881 | Carpentier et al. | Mar 1987 | A |
4655218 | Kulik et al. | Apr 1987 | A |
4655771 | Wallsten et al. | Apr 1987 | A |
4662885 | DiPisa | May 1987 | A |
4665906 | Jervis | May 1987 | A |
4680031 | Alonso | Jul 1987 | A |
4692164 | Dzemeshkevich et al. | Sep 1987 | A |
4705516 | Barone et al. | Nov 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4733665 | Palmaz et al. | Mar 1988 | A |
4739759 | Rexroth et al. | Apr 1988 | A |
4755181 | Igoe | Jul 1988 | A |
4759758 | Gabbay | Jul 1988 | A |
4777951 | Cribier et al. | Oct 1988 | A |
4787899 | Lazarus | Nov 1988 | A |
4787901 | Baykut | Nov 1988 | A |
4796629 | Grayzel | Jan 1989 | A |
4819751 | Shimada et al. | Apr 1989 | A |
4829990 | Thuroff et al. | May 1989 | A |
4834755 | Silvestrini et al. | May 1989 | A |
4851001 | Taheri | Jul 1989 | A |
4856516 | Hillstead | Aug 1989 | A |
4865600 | Carpentier et al. | Sep 1989 | A |
4872874 | Taheri | Oct 1989 | A |
4873978 | Ginsburg | Oct 1989 | A |
4878495 | Grayzel | Nov 1989 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4883458 | Shiber | Nov 1989 | A |
4885005 | Nashef et al. | Dec 1989 | A |
4909252 | Goldberger | Mar 1990 | A |
4917102 | Miller et al. | Apr 1990 | A |
4922905 | Strecker | May 1990 | A |
4927426 | Dretler | May 1990 | A |
4954126 | Wallsten | Sep 1990 | A |
4966604 | Reiss | Oct 1990 | A |
4969890 | Sugita et al. | Nov 1990 | A |
4979939 | Shiber | Dec 1990 | A |
4986830 | Owens et al. | Jan 1991 | A |
4994077 | Dobben | Feb 1991 | A |
5002556 | Ishida et al. | Mar 1991 | A |
5002559 | Tower | Mar 1991 | A |
5007896 | Shiber | Apr 1991 | A |
5026366 | Leckrone | Jun 1991 | A |
5032128 | Alonso | Jul 1991 | A |
5037434 | Lane | Aug 1991 | A |
5047041 | Samuels | Sep 1991 | A |
5064435 | Porter | Nov 1991 | A |
5080668 | Bolz et al. | Jan 1992 | A |
5085635 | Cragg | Feb 1992 | A |
5089015 | Ross | Feb 1992 | A |
5122154 | Rhodes | Jun 1992 | A |
5132473 | Furutaka et al. | Jul 1992 | A |
5141494 | Danforth et al. | Aug 1992 | A |
5152771 | Sabbaghian et al. | Oct 1992 | A |
5159937 | Tremulis | Nov 1992 | A |
5161547 | Tower | Nov 1992 | A |
5163953 | Vince | Nov 1992 | A |
5167628 | Boyles | Dec 1992 | A |
5209741 | Spaeth | May 1993 | A |
5215541 | Nashef et al. | Jun 1993 | A |
5217481 | Barbara | Jun 1993 | A |
5217483 | Tower | Jun 1993 | A |
5238004 | Sahatjian et al. | Aug 1993 | A |
5258023 | Reger | Nov 1993 | A |
5258042 | Mehta | Nov 1993 | A |
5282847 | Trescony et al. | Feb 1994 | A |
5295958 | Shturman | Mar 1994 | A |
5326372 | Mhatre et al. | Jul 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5336258 | Quintero et al. | Aug 1994 | A |
5350398 | Pavcnik et al. | Sep 1994 | A |
5360444 | Kusuhara | Nov 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5389106 | Tower | Feb 1995 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5409019 | Wilk | Apr 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5425739 | Jessen | Jun 1995 | A |
5425762 | Muller | Jun 1995 | A |
5431676 | Dubrul et al. | Jul 1995 | A |
5443446 | Shturman | Aug 1995 | A |
5443449 | Buelna | Aug 1995 | A |
5443477 | Marin et al. | Aug 1995 | A |
5443495 | Buscemi et al. | Aug 1995 | A |
5443499 | Schmitt | Aug 1995 | A |
5469868 | Reger | Nov 1995 | A |
5476506 | Lunn | Dec 1995 | A |
5476510 | Eberhardt et al. | Dec 1995 | A |
5480423 | Ravenscroft et al. | Jan 1996 | A |
5480424 | Cox | Jan 1996 | A |
5489297 | Duran | Feb 1996 | A |
5500014 | Quijano et al. | Mar 1996 | A |
5507767 | Maeda et al. | Apr 1996 | A |
5522881 | Lentz | Jun 1996 | A |
5534007 | Germain et al. | Jul 1996 | A |
5545133 | Burns et al. | Aug 1996 | A |
5545209 | Roberts et al. | Aug 1996 | A |
5545211 | An et al. | Aug 1996 | A |
5545214 | Stevens | Aug 1996 | A |
5549665 | Vesely et al. | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5571175 | Vanney et al. | Nov 1996 | A |
5571215 | Sterman et al. | Nov 1996 | A |
5573520 | Schwartz et al. | Nov 1996 | A |
5575818 | Pinchuk | Nov 1996 | A |
5591185 | Kilmer et al. | Jan 1997 | A |
5591195 | Faheri et al. | Jan 1997 | A |
5607464 | Frescony et al. | Mar 1997 | A |
5609626 | Quijano et al. | Mar 1997 | A |
5628784 | Strecker | May 1997 | A |
5645559 | Hachtman et al. | Jul 1997 | A |
5653745 | Trescony et al. | Aug 1997 | A |
5662671 | Barbut et al. | Sep 1997 | A |
5667523 | Bynon et al. | Sep 1997 | A |
5674277 | Freitag | Oct 1997 | A |
5681345 | Euteneuer | Oct 1997 | A |
5693083 | Baker et al. | Dec 1997 | A |
5693088 | Lazarus | Dec 1997 | A |
5693310 | Gries et al. | Dec 1997 | A |
5695498 | Tower | Dec 1997 | A |
5709713 | Evans et al. | Jan 1998 | A |
5713951 | Garrison et al. | Feb 1998 | A |
5713953 | Vallana et al. | Feb 1998 | A |
5716370 | Williamson et al. | Feb 1998 | A |
5716417 | Girard et al. | Feb 1998 | A |
5720391 | Dohm et al. | Feb 1998 | A |
5725549 | Lam | Mar 1998 | A |
5728068 | Leone et al. | Mar 1998 | A |
5733325 | Robinson et al. | Mar 1998 | A |
5735842 | Krueger et al. | Apr 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5755783 | Stobie et al. | May 1998 | A |
5756476 | Epstein et al. | May 1998 | A |
5769812 | Stevens et al. | Jun 1998 | A |
5769882 | Fogarty et al. | Jun 1998 | A |
5772609 | Nguyen et al. | Jun 1998 | A |
5776188 | Shepherd et al. | Jul 1998 | A |
5782904 | White et al. | Jul 1998 | A |
5800456 | Maeda et al. | Sep 1998 | A |
5800531 | Cosgrove et al. | Sep 1998 | A |
5807405 | Vanney et al. | Sep 1998 | A |
5817126 | Imran | Oct 1998 | A |
5824037 | Fogarty et al. | Oct 1998 | A |
5824041 | Lenker et al. | Oct 1998 | A |
5824043 | Cottone | Oct 1998 | A |
5824053 | Khosravi et al. | Oct 1998 | A |
5824055 | Spiridigliozzi et al. | Oct 1998 | A |
5824056 | Rosenberg | Oct 1998 | A |
5824064 | Taheri | Oct 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5843158 | Lenker et al. | Dec 1998 | A |
5843161 | Solovay | Dec 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5855602 | Angell | Jan 1999 | A |
5860966 | Tower | Jan 1999 | A |
5860996 | Urban et al. | Jan 1999 | A |
5861024 | Rashidi | Jan 1999 | A |
5861028 | Angell | Jan 1999 | A |
5868783 | Tower | Feb 1999 | A |
5876419 | Carpenter et al. | Mar 1999 | A |
5876448 | Thompson et al. | Mar 1999 | A |
5885228 | Rosenman et al. | Mar 1999 | A |
5888201 | Stinson et al. | Mar 1999 | A |
5891191 | Stinson | Apr 1999 | A |
5895399 | Barbut et al. | Apr 1999 | A |
5906619 | Olson et al. | May 1999 | A |
5907893 | Zadno-Azizi et al. | Jun 1999 | A |
5910154 | Tsugita et al. | Jun 1999 | A |
5911734 | Tsugita et al. | Jun 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5954766 | Zadno-Azizi et al. | Sep 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5968070 | Bley et al. | Oct 1999 | A |
5984957 | Laptewicz et al. | Nov 1999 | A |
5984959 | Robertson et al. | Nov 1999 | A |
5993469 | McKenzie et al. | Nov 1999 | A |
5997557 | Barbut et al. | Dec 1999 | A |
6010522 | Barbut et al. | Jan 2000 | A |
6015431 | Thornton et al. | Jan 2000 | A |
6022370 | Tower | Feb 2000 | A |
6027520 | Tsugita et al. | Feb 2000 | A |
6027525 | Suh et al. | Feb 2000 | A |
6042598 | Tsugita et al. | Mar 2000 | A |
6042607 | Williamson et al. | Mar 2000 | A |
6045576 | Starr et al. | Apr 2000 | A |
6051014 | Jang | Apr 2000 | A |
6059827 | Fenton | May 2000 | A |
6074418 | Buchanan et al. | Jun 2000 | A |
6093203 | Uflacker | Jul 2000 | A |
6096074 | Pedros | Aug 2000 | A |
6110198 | Fogarty et al. | Aug 2000 | A |
6123723 | Konya et al. | Sep 2000 | A |
6132473 | Williams et al. | Oct 2000 | A |
6139510 | Palermo | Oct 2000 | A |
6142987 | Fsugita | Nov 2000 | A |
6146366 | Schachar | Nov 2000 | A |
6162245 | Jayaraman | Dec 2000 | A |
6165200 | Tsugita et al. | Dec 2000 | A |
6165209 | Patterson et al. | Dec 2000 | A |
6168579 | Tsugita | Jan 2001 | B1 |
6168614 | Andersen et al. | Jan 2001 | B1 |
6171327 | Daniel et al. | Jan 2001 | B1 |
6171335 | Wheatley et al. | Jan 2001 | B1 |
6179859 | Bates et al. | Jan 2001 | B1 |
6187016 | Hedges et al. | Feb 2001 | B1 |
6197053 | Cosgrove et al. | Mar 2001 | B1 |
6200336 | Pavcnik et al. | Mar 2001 | B1 |
6206911 | Milo | Mar 2001 | B1 |
6214036 | Letendre et al. | Apr 2001 | B1 |
6221006 | Dubrul et al. | Apr 2001 | B1 |
6221091 | Khosravi | Apr 2001 | B1 |
6221096 | Aiba et al. | Apr 2001 | B1 |
6221100 | Strecker | Apr 2001 | B1 |
6231544 | Tsugita et al. | May 2001 | B1 |
6231551 | Barbut | May 2001 | B1 |
6241757 | An et al. | Jun 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6251135 | Stinson et al. | Jun 2001 | B1 |
6254636 | Peredo | Jul 2001 | B1 |
6258114 | Konya et al. | Jul 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6258120 | McKenzie et al. | Jul 2001 | B1 |
6258129 | Dybdal et al. | Jul 2001 | B1 |
6267783 | Letendre et al. | Jul 2001 | B1 |
6270513 | Tsugita et al. | Aug 2001 | B1 |
6277555 | Duran et al. | Aug 2001 | B1 |
6299637 | Shaolian et al. | Oct 2001 | B1 |
6302906 | Goicoechea et al. | Oct 2001 | B1 |
6306164 | Kujawski | Oct 2001 | B1 |
6309417 | Spence et al. | Oct 2001 | B1 |
6312465 | Griffin et al. | Nov 2001 | B1 |
6319281 | Patel | Nov 2001 | B1 |
6327772 | Zadno-Azizi et al. | Dec 2001 | B1 |
6336934 | Gilson et al. | Jan 2002 | B1 |
6336937 | Vonesh et al. | Jan 2002 | B1 |
6338735 | Stevens | Jan 2002 | B1 |
6346116 | Brooks et al. | Feb 2002 | B1 |
6348063 | Yassour et al. | Feb 2002 | B1 |
6350282 | Eberhardt | Feb 2002 | B1 |
6352554 | Paulis | Mar 2002 | B2 |
6352708 | Duran et al. | Mar 2002 | B1 |
6361545 | Macoviak et al. | Mar 2002 | B1 |
6363938 | Saadat et al. | Apr 2002 | B2 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6371970 | Khosravi et al. | Apr 2002 | B1 |
6371983 | Lane | Apr 2002 | B1 |
6379383 | Palmaz et al. | Apr 2002 | B1 |
6387122 | Cragg | May 2002 | B1 |
6398807 | Chouinard et al. | Jun 2002 | B1 |
6402736 | Brown et al. | Jun 2002 | B1 |
6409750 | Hyodoh et al. | Jun 2002 | B1 |
6416510 | Altman et al. | Jul 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6440164 | DiMatteo et al. | Aug 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6461382 | Cao | Oct 2002 | B1 |
6468303 | Amplatz et al. | Oct 2002 | B1 |
6468660 | Ogle et al. | Oct 2002 | B2 |
6475239 | Campbell et al. | Nov 2002 | B1 |
6482228 | Norred | Nov 2002 | B1 |
6485501 | Green | Nov 2002 | B1 |
6485502 | Michael et al. | Nov 2002 | B2 |
6488704 | Connelly et al. | Dec 2002 | B1 |
6494909 | Greenhalgh | Dec 2002 | B2 |
6503272 | Duerig et al. | Jan 2003 | B2 |
6508803 | Horikawa et al. | Jan 2003 | B1 |
6508833 | Pavcnik et al. | Jan 2003 | B2 |
6527800 | McGuckin et al. | Mar 2003 | B1 |
6530949 | Konya et al. | Mar 2003 | B2 |
6530952 | Vesely | Mar 2003 | B2 |
6537297 | Tsugita et al. | Mar 2003 | B2 |
6540768 | Diaz et al. | Apr 2003 | B1 |
6540782 | Snyders | Apr 2003 | B1 |
6558417 | Peredo | May 2003 | B2 |
6562058 | Seguin et al. | May 2003 | B2 |
6569196 | Vesely | May 2003 | B1 |
6572643 | Gharibadeh | Jun 2003 | B1 |
6585766 | Huynh et al. | Jul 2003 | B1 |
6592546 | Barbut et al. | Jul 2003 | B1 |
6592614 | Lenker et al. | Jul 2003 | B2 |
6605112 | Moll et al. | Aug 2003 | B1 |
6610077 | Hancock et al. | Aug 2003 | B1 |
6616682 | Joergensen et al. | Sep 2003 | B2 |
6622604 | Chouinard et al. | Sep 2003 | B1 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6623521 | Steinke et al. | Sep 2003 | B2 |
6626938 | Butaric et al. | Sep 2003 | B1 |
6632243 | Zadno-Azizi et al. | Oct 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6635079 | Unsworth et al. | Oct 2003 | B2 |
6635080 | Lauterjung et al. | Oct 2003 | B1 |
6652571 | White et al. | Nov 2003 | B1 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6663588 | DuBois et al. | Dec 2003 | B2 |
6663663 | Kim et al. | Dec 2003 | B2 |
6663667 | Dehdashtian et al. | Dec 2003 | B2 |
6669724 | Park et al. | Dec 2003 | B2 |
6673089 | Yassour et al. | Jan 2004 | B1 |
6673109 | Cox | Jan 2004 | B2 |
6676668 | Mercereau et al. | Jan 2004 | B2 |
6676692 | Rabkin et al. | Jan 2004 | B2 |
6676698 | McGuckin et al. | Jan 2004 | B2 |
6682543 | Barbut et al. | Jan 2004 | B2 |
6682558 | Tu et al. | Jan 2004 | B2 |
6682559 | Myers et al. | Jan 2004 | B2 |
6685739 | DiMatteo et al. | Feb 2004 | B2 |
6689144 | Gerberding | Feb 2004 | B2 |
6689164 | Seguin | Feb 2004 | B1 |
6692512 | Jang | Feb 2004 | B2 |
6695864 | Macoviak et al. | Feb 2004 | B2 |
6695865 | Boyle et al. | Feb 2004 | B2 |
6702851 | Chinn et al. | Mar 2004 | B1 |
6712842 | Gifford et al. | Mar 2004 | B1 |
6712843 | Elliott | Mar 2004 | B2 |
6714842 | Ito | Mar 2004 | B1 |
6719789 | Cox | Apr 2004 | B2 |
6723116 | Taheri | Apr 2004 | B2 |
6729356 | Baker et al. | May 2004 | B1 |
6730118 | Spenser et al. | May 2004 | B2 |
6730377 | Wang | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6736846 | Cox | May 2004 | B2 |
6752828 | Thornton | Jun 2004 | B2 |
6755854 | Gillick et al. | Jun 2004 | B2 |
6758855 | Fulton et al. | Jul 2004 | B2 |
6764503 | Ishimaru | Jul 2004 | B1 |
6764509 | Chinn et al. | Jul 2004 | B2 |
6767345 | Germain et al. | Jul 2004 | B2 |
6769434 | Liddicoat et al. | Aug 2004 | B2 |
6773454 | Wholey et al. | Aug 2004 | B2 |
6773456 | Gordon et al. | Aug 2004 | B1 |
6776791 | Stallings et al. | Aug 2004 | B1 |
6786925 | Schoon et al. | Sep 2004 | B1 |
6790229 | Berreklouw | Sep 2004 | B1 |
6790230 | Beyersdorf et al. | Sep 2004 | B2 |
6790237 | Stinson | Sep 2004 | B2 |
6792979 | Konya et al. | Sep 2004 | B2 |
6797002 | Spence et al. | Sep 2004 | B2 |
6814746 | Thompson et al. | Nov 2004 | B2 |
6814754 | Greenhalgh | Nov 2004 | B2 |
6821297 | Snyders | Nov 2004 | B2 |
6824041 | Grieder et al. | Nov 2004 | B2 |
6830585 | Artof et al. | Dec 2004 | B1 |
6837901 | Rabkin et al. | Jan 2005 | B2 |
6840957 | DiMatteo et al. | Jan 2005 | B2 |
6843802 | Villalobos et al. | Jan 2005 | B1 |
6849085 | Marton | Feb 2005 | B2 |
6863668 | Gillespie et al. | Mar 2005 | B2 |
6863688 | Ralph et al. | Mar 2005 | B2 |
6866650 | Stevens et al. | Mar 2005 | B2 |
6866669 | Buzzard et al. | Mar 2005 | B2 |
6872223 | Roberts et al. | Mar 2005 | B2 |
6872226 | Cali et al. | Mar 2005 | B2 |
6875231 | Anduiza et al. | Apr 2005 | B2 |
6881220 | Edwin et al. | Apr 2005 | B2 |
6883522 | Spence et al. | Apr 2005 | B2 |
6887266 | Williams et al. | May 2005 | B2 |
6890340 | Duane | May 2005 | B2 |
6893459 | Macoviak | May 2005 | B1 |
6893460 | Spenser et al. | May 2005 | B2 |
6896690 | Lambrecht et al. | May 2005 | B1 |
6905743 | Chen et al. | Jun 2005 | B1 |
6908481 | Cribier | Jun 2005 | B2 |
6911036 | Douk et al. | Jun 2005 | B2 |
6911040 | Johnson et al. | Jun 2005 | B2 |
6911043 | Myers et al. | Jun 2005 | B2 |
6936058 | Forde et al. | Aug 2005 | B2 |
6936067 | Buchanan | Aug 2005 | B2 |
6939352 | Buzzard et al. | Sep 2005 | B2 |
6951571 | Srivastava | Oct 2005 | B1 |
6951573 | Dilling | Oct 2005 | B1 |
6953332 | Kurk et al. | Oct 2005 | B1 |
6964673 | Tsugita et al. | Nov 2005 | B2 |
6969395 | Eskuri | Nov 2005 | B2 |
6972025 | WasDyke | Dec 2005 | B2 |
6974464 | Quijano et al. | Dec 2005 | B2 |
6974474 | Pavcnik et al. | Dec 2005 | B2 |
6974476 | McGuckin et al. | Dec 2005 | B2 |
6979350 | Moll et al. | Dec 2005 | B2 |
6984242 | Campbell et al. | Jan 2006 | B2 |
6989027 | Allen et al. | Jan 2006 | B2 |
7004176 | Lau | Feb 2006 | B2 |
7011681 | Vesely | Mar 2006 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7025791 | Levine et al. | Apr 2006 | B2 |
7037331 | Mitelberg et al. | May 2006 | B2 |
7041132 | Quijano et al. | May 2006 | B2 |
7044966 | Svanidze et al. | May 2006 | B2 |
7097658 | Oktay | Aug 2006 | B2 |
7108715 | Lawrence-Brown et al. | Sep 2006 | B2 |
7122020 | Mogul | Oct 2006 | B2 |
7125418 | Duran et al. | Oct 2006 | B2 |
7141063 | White et al. | Nov 2006 | B2 |
7147663 | Berg et al. | Dec 2006 | B1 |
7166097 | Barbut | Jan 2007 | B2 |
7172625 | Shu et al. | Feb 2007 | B2 |
7175652 | Cook et al. | Feb 2007 | B2 |
7175653 | Gaber | Feb 2007 | B2 |
7175654 | Bonsignore et al. | Feb 2007 | B2 |
7175656 | Khairkhahan | Feb 2007 | B2 |
7175659 | Hill et al. | Feb 2007 | B2 |
7189258 | Johnson et al. | Mar 2007 | B2 |
7191018 | Gielen et al. | Mar 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7235093 | Gregorich | Jun 2007 | B2 |
7252682 | Seguin | Aug 2007 | B2 |
7258696 | Rabkin et al. | Aug 2007 | B2 |
7261732 | Justino | Aug 2007 | B2 |
7264632 | Wright et al. | Sep 2007 | B2 |
7267686 | DiMatteo et al. | Sep 2007 | B2 |
7276078 | Spenser et al. | Oct 2007 | B2 |
7318278 | Zhang et al. | Jan 2008 | B2 |
7322932 | Xie et al. | Jan 2008 | B2 |
7326236 | Andreas et al. | Feb 2008 | B2 |
7329279 | Haug et al. | Feb 2008 | B2 |
7331993 | White | Feb 2008 | B2 |
7374560 | Ressemann et al. | May 2008 | B2 |
7381219 | Salahieh et al. | Jun 2008 | B2 |
7381220 | Macoviak et al. | Jun 2008 | B2 |
7399315 | Tobbi | Jul 2008 | B2 |
7445631 | Salahieh et al. | Nov 2008 | B2 |
7470285 | Nugent et al. | Dec 2008 | B2 |
7491232 | Bolduc et al. | Feb 2009 | B2 |
7510574 | Lê et al. | Mar 2009 | B2 |
7524330 | Berreklouw | Apr 2009 | B2 |
7524331 | Birdsall | Apr 2009 | B2 |
7530995 | Quijano et al. | May 2009 | B2 |
7544206 | Cohn | Jun 2009 | B2 |
7575594 | Sieracki | Aug 2009 | B2 |
7622276 | Cunanan et al. | Nov 2009 | B2 |
7628803 | Pavcnik et al. | Dec 2009 | B2 |
7632298 | Hijlkema et al. | Dec 2009 | B2 |
7641687 | Chinn et al. | Jan 2010 | B2 |
7670370 | Hill et al. | Mar 2010 | B2 |
7674282 | Wu et al. | Mar 2010 | B2 |
7712606 | Salahieh et al. | May 2010 | B2 |
7717955 | Lane et al. | May 2010 | B2 |
7722638 | Deyette et al. | May 2010 | B2 |
7722662 | Steinke et al. | May 2010 | B2 |
7722666 | Lafontaine | May 2010 | B2 |
7731742 | Schlick et al. | Jun 2010 | B2 |
7736388 | Goldfarb et al. | Jun 2010 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7758625 | Wu et al. | Jul 2010 | B2 |
7780725 | Haug et al. | Aug 2010 | B2 |
7799065 | Pappas | Sep 2010 | B2 |
7803185 | Gabbay | Sep 2010 | B2 |
7819915 | Stobie et al. | Oct 2010 | B2 |
7824442 | Salahieh et al. | Nov 2010 | B2 |
7824443 | Salahieh et al. | Nov 2010 | B2 |
7833262 | McGuckin et al. | Nov 2010 | B2 |
7846204 | Letac et al. | Dec 2010 | B2 |
7857845 | Stacchino et al. | Dec 2010 | B2 |
7892281 | Seguin et al. | Feb 2011 | B2 |
7892292 | Stack et al. | Feb 2011 | B2 |
7918880 | Austin | Apr 2011 | B2 |
7938851 | Olson et al. | May 2011 | B2 |
7959666 | Salahieh et al. | Jun 2011 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
7988724 | Salahieh et al. | Aug 2011 | B2 |
7993394 | Hariton et al. | Aug 2011 | B2 |
8012135 | Dann et al. | Sep 2011 | B2 |
8029564 | Johnson et al. | Oct 2011 | B2 |
8048153 | Salahieh et al. | Nov 2011 | B2 |
8052749 | Salahieh et al. | Nov 2011 | B2 |
8075611 | Millwee et al. | Dec 2011 | B2 |
8136659 | Salahieh et al. | Mar 2012 | B2 |
8157853 | Laske et al. | Apr 2012 | B2 |
8163014 | Lane et al. | Apr 2012 | B2 |
8172892 | Chuter et al. | May 2012 | B2 |
8172896 | McNamara et al. | May 2012 | B2 |
8182528 | Salahieh et al. | May 2012 | B2 |
8192351 | Fishier et al. | Jun 2012 | B2 |
8226710 | Nguyen et al. | Jul 2012 | B2 |
8231670 | Salahieh et al. | Jul 2012 | B2 |
8236049 | Rowe et al. | Aug 2012 | B2 |
8246678 | Salahieh et al. | Aug 2012 | B2 |
8252051 | Chau et al. | Aug 2012 | B2 |
8252052 | Salahieh et al. | Aug 2012 | B2 |
8287584 | Salahieh et al. | Oct 2012 | B2 |
8308798 | Pintor et al. | Nov 2012 | B2 |
8317858 | Straubinger et al. | Nov 2012 | B2 |
8323335 | Rowe et al. | Dec 2012 | B2 |
8328868 | Paul et al. | Dec 2012 | B2 |
8343213 | Salahieh et al. | Jan 2013 | B2 |
8376865 | Forster et al. | Feb 2013 | B2 |
8377117 | Keidar et al. | Feb 2013 | B2 |
8398708 | Meiri et al. | Mar 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8414644 | Quadri et al. | Apr 2013 | B2 |
8579962 | Salahieh et al. | Nov 2013 | B2 |
8603160 | Salahieh et al. | Dec 2013 | B2 |
8617236 | Paul et al. | Dec 2013 | B2 |
8623074 | Ryan | Jan 2014 | B2 |
8623076 | Salahieh et al. | Jan 2014 | B2 |
8623078 | Salahieh et al. | Jan 2014 | B2 |
8668733 | Haug et al. | Mar 2014 | B2 |
8696737 | Gainor | Apr 2014 | B2 |
8696743 | Holecek et al. | Apr 2014 | B2 |
8778020 | Gregg et al. | Jul 2014 | B2 |
8828078 | Salahieh et al. | Sep 2014 | B2 |
8840662 | Salahieh et al. | Sep 2014 | B2 |
8840663 | Salahieh et al. | Sep 2014 | B2 |
8858620 | Salahieh et al. | Oct 2014 | B2 |
8894703 | Salahieh et al. | Nov 2014 | B2 |
8951299 | Paul et al. | Feb 2015 | B2 |
8992608 | Haug et al. | Mar 2015 | B2 |
9005273 | Salahieh et al. | Apr 2015 | B2 |
9011521 | Haug et al. | Apr 2015 | B2 |
9168129 | Valdez et al. | Oct 2015 | B2 |
9168131 | Yohanan et al. | Oct 2015 | B2 |
9675451 | Garde et al. | Jun 2017 | B2 |
9861477 | Backus et al. | Jan 2018 | B2 |
9895225 | Rolando et al. | Feb 2018 | B2 |
9974649 | Racchini et al. | May 2018 | B2 |
10080652 | Backus et al. | Sep 2018 | B2 |
10136991 | Backus et al. | Nov 2018 | B2 |
10327892 | O'Connor et al. | Jun 2019 | B2 |
10405974 | Hayes | Sep 2019 | B2 |
20010002445 | Vesely | May 2001 | A1 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20010010017 | Letac et al. | Jul 2001 | A1 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010025196 | Chinn et al. | Sep 2001 | A1 |
20010027338 | Greenberg | Oct 2001 | A1 |
20010032013 | Marton | Oct 2001 | A1 |
20010039450 | Pavcnik et al. | Nov 2001 | A1 |
20010041928 | Pavcnik et al. | Nov 2001 | A1 |
20010041930 | Globerman et al. | Nov 2001 | A1 |
20010044634 | Michael et al. | Nov 2001 | A1 |
20010044652 | Moore | Nov 2001 | A1 |
20010044656 | Williamson et al. | Nov 2001 | A1 |
20020002396 | Fulkerson | Jan 2002 | A1 |
20020010489 | Grayzel et al. | Jan 2002 | A1 |
20020026233 | Shaknovich | Feb 2002 | A1 |
20020029014 | Jayaraman | Mar 2002 | A1 |
20020029981 | Nigam | Mar 2002 | A1 |
20020032480 | Spence et al. | Mar 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020042651 | Liddicoat et al. | Apr 2002 | A1 |
20020052651 | Myers et al. | May 2002 | A1 |
20020055767 | Forde et al. | May 2002 | A1 |
20020055769 | Wang | May 2002 | A1 |
20020055774 | Liddicoat | May 2002 | A1 |
20020058987 | Butaric et al. | May 2002 | A1 |
20020058994 | Hill et al. | May 2002 | A1 |
20020058995 | Stevens | May 2002 | A1 |
20020077696 | Zadno-Azizi et al. | Jun 2002 | A1 |
20020077698 | Peredo | Jun 2002 | A1 |
20020082609 | Green | Jun 2002 | A1 |
20020095173 | Mazzocchi et al. | Jul 2002 | A1 |
20020095209 | Zadno-Azizi et al. | Jul 2002 | A1 |
20020111674 | Chouinard et al. | Aug 2002 | A1 |
20020120328 | Pathak et al. | Aug 2002 | A1 |
20020123802 | Snyders | Sep 2002 | A1 |
20020138138 | Yang | Sep 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20020156522 | Ivancev et al. | Oct 2002 | A1 |
20020161390 | Mouw | Oct 2002 | A1 |
20020161392 | Dubrul | Oct 2002 | A1 |
20020161394 | Macoviak et al. | Oct 2002 | A1 |
20020165576 | Boyle et al. | Nov 2002 | A1 |
20020177766 | Mogul | Nov 2002 | A1 |
20020183781 | Casey et al. | Dec 2002 | A1 |
20020188341 | Elliott | Dec 2002 | A1 |
20020188344 | Bolea et al. | Dec 2002 | A1 |
20020193871 | Beyersdorf et al. | Dec 2002 | A1 |
20030014104 | Cribier | Jan 2003 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030028247 | Cali | Feb 2003 | A1 |
20030036791 | Philipp et al. | Feb 2003 | A1 |
20030040736 | Stevens et al. | Feb 2003 | A1 |
20030040771 | Hyodoh et al. | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030040791 | Oktay | Feb 2003 | A1 |
20030040792 | Gabbay | Feb 2003 | A1 |
20030050694 | Fang et al. | Mar 2003 | A1 |
20030055495 | Pease et al. | Mar 2003 | A1 |
20030057156 | Peterson et al. | Mar 2003 | A1 |
20030060844 | Borillo et al. | Mar 2003 | A1 |
20030069492 | Abrams et al. | Apr 2003 | A1 |
20030069646 | Stinson | Apr 2003 | A1 |
20030070944 | Nigam | Apr 2003 | A1 |
20030074058 | Sherry | Apr 2003 | A1 |
20030093145 | Lawrence-Brown et al. | May 2003 | A1 |
20030100918 | Duane | May 2003 | A1 |
20030100919 | Hopkins et al. | May 2003 | A1 |
20030109924 | Cribier | Jun 2003 | A1 |
20030109930 | Bluni et al. | Jun 2003 | A1 |
20030114912 | Sequin et al. | Jun 2003 | A1 |
20030114913 | Spenser et al. | Jun 2003 | A1 |
20030114924 | Moe | Jun 2003 | A1 |
20030125795 | Pavcnik et al. | Jul 2003 | A1 |
20030130729 | Paniagua et al. | Jul 2003 | A1 |
20030135257 | Taheri | Jul 2003 | A1 |
20030144732 | Cosgrove et al. | Jul 2003 | A1 |
20030149475 | Hyodoh et al. | Aug 2003 | A1 |
20030149476 | Damm et al. | Aug 2003 | A1 |
20030149478 | Figulla et al. | Aug 2003 | A1 |
20030153974 | Spenser et al. | Aug 2003 | A1 |
20030165352 | Ibrahim et al. | Sep 2003 | A1 |
20030171803 | Shimon | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030176912 | Chuter et al. | Sep 2003 | A1 |
20030181850 | Diamond et al. | Sep 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030191516 | Weldon et al. | Oct 2003 | A1 |
20030195609 | Berenstein et al. | Oct 2003 | A1 |
20030195620 | Huynh et al. | Oct 2003 | A1 |
20030199759 | Richard | Oct 2003 | A1 |
20030199913 | Dubrul et al. | Oct 2003 | A1 |
20030199971 | Tower et al. | Oct 2003 | A1 |
20030199972 | Zadno-Azizi et al. | Oct 2003 | A1 |
20030204249 | Letort | Oct 2003 | A1 |
20030208224 | Broome | Nov 2003 | A1 |
20030212429 | Keegan et al. | Nov 2003 | A1 |
20030212452 | Zadno-Azizi et al. | Nov 2003 | A1 |
20030212454 | Scott et al. | Nov 2003 | A1 |
20030216774 | Larson | Nov 2003 | A1 |
20030225445 | Derus et al. | Dec 2003 | A1 |
20030229390 | Ashton et al. | Dec 2003 | A1 |
20030233117 | Adams et al. | Dec 2003 | A1 |
20030236567 | Elliot | Dec 2003 | A1 |
20040015232 | Shu et al. | Jan 2004 | A1 |
20040019374 | Hojeibane et al. | Jan 2004 | A1 |
20040030381 | Shu | Feb 2004 | A1 |
20040033364 | Spiridigliozzi et al. | Feb 2004 | A1 |
20040034411 | Quijano et al. | Feb 2004 | A1 |
20040039436 | Spenser et al. | Feb 2004 | A1 |
20040049224 | Buehlmann et al. | Mar 2004 | A1 |
20040049226 | Keegan et al. | Mar 2004 | A1 |
20040049262 | Obermiller et al. | Mar 2004 | A1 |
20040049266 | Anduiza et al. | Mar 2004 | A1 |
20040059409 | Stenzel | Mar 2004 | A1 |
20040073198 | Gilson et al. | Apr 2004 | A1 |
20040082904 | Houde et al. | Apr 2004 | A1 |
20040082967 | Broome et al. | Apr 2004 | A1 |
20040082989 | Cook et al. | Apr 2004 | A1 |
20040087982 | Eskuri | May 2004 | A1 |
20040088045 | Cox | May 2004 | A1 |
20040093016 | Root et al. | May 2004 | A1 |
20040093060 | Seguin et al. | May 2004 | A1 |
20040097788 | Mourlas et al. | May 2004 | A1 |
20040098022 | Barone | May 2004 | A1 |
20040098098 | McGuckin et al. | May 2004 | A1 |
20040098099 | McCullagh et al. | May 2004 | A1 |
20040098112 | DiMatteo et al. | May 2004 | A1 |
20040106990 | Spence et al. | Jun 2004 | A1 |
20040107004 | Levine et al. | Jun 2004 | A1 |
20040111096 | Tu et al. | Jun 2004 | A1 |
20040116951 | Rosengart | Jun 2004 | A1 |
20040116999 | Ledergerber | Jun 2004 | A1 |
20040117004 | Osborne et al. | Jun 2004 | A1 |
20040117009 | Cali et al. | Jun 2004 | A1 |
20040122468 | Yodfat et al. | Jun 2004 | A1 |
20040122516 | Fogarty et al. | Jun 2004 | A1 |
20040127936 | Salahieh et al. | Jul 2004 | A1 |
20040127979 | Wilson et al. | Jul 2004 | A1 |
20040133274 | Webler et al. | Jul 2004 | A1 |
20040138694 | Tran et al. | Jul 2004 | A1 |
20040138742 | Myers et al. | Jul 2004 | A1 |
20040138743 | Myers et al. | Jul 2004 | A1 |
20040148018 | Carpentier et al. | Jul 2004 | A1 |
20040148021 | Cartledge et al. | Jul 2004 | A1 |
20040153094 | Dunfee et al. | Aug 2004 | A1 |
20040158277 | Lowe et al. | Aug 2004 | A1 |
20040167565 | Beulke et al. | Aug 2004 | A1 |
20040167620 | Ortiz et al. | Aug 2004 | A1 |
20040181140 | Falwell et al. | Sep 2004 | A1 |
20040186558 | Pavcnik et al. | Sep 2004 | A1 |
20040186563 | Lobbi | Sep 2004 | A1 |
20040193261 | Berreklouw | Sep 2004 | A1 |
20040197695 | Aono | Oct 2004 | A1 |
20040199245 | Lauterjung | Oct 2004 | A1 |
20040204755 | Robin | Oct 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040210306 | Quijano et al. | Oct 2004 | A1 |
20040210307 | Khairkhahan | Oct 2004 | A1 |
20040215331 | Chew et al. | Oct 2004 | A1 |
20040215333 | Duran et al. | Oct 2004 | A1 |
20040215339 | Drasler et al. | Oct 2004 | A1 |
20040220655 | Swanson et al. | Nov 2004 | A1 |
20040225321 | Krolik et al. | Nov 2004 | A1 |
20040225352 | Osborne | Nov 2004 | A1 |
20040225353 | McGuckin et al. | Nov 2004 | A1 |
20040225354 | Allen et al. | Nov 2004 | A1 |
20040225355 | Stevens | Nov 2004 | A1 |
20040243221 | Fawzi et al. | Dec 2004 | A1 |
20040254636 | Flagle et al. | Dec 2004 | A1 |
20040260390 | Sarac et al. | Dec 2004 | A1 |
20050010287 | Macoviak et al. | Jan 2005 | A1 |
20050021136 | Xie et al. | Jan 2005 | A1 |
20050033398 | Seguin | Feb 2005 | A1 |
20050033402 | Cully et al. | Feb 2005 | A1 |
20050043711 | Corcoran et al. | Feb 2005 | A1 |
20050043757 | Arad et al. | Feb 2005 | A1 |
20050043790 | Seguin | Feb 2005 | A1 |
20050049692 | Numamoto et al. | Mar 2005 | A1 |
20050049696 | Siess et al. | Mar 2005 | A1 |
20050055088 | Liddicoat et al. | Mar 2005 | A1 |
20050060016 | Wu et al. | Mar 2005 | A1 |
20050060029 | Le et al. | Mar 2005 | A1 |
20050065594 | DiMatteo et al. | Mar 2005 | A1 |
20050075584 | Cali | Apr 2005 | A1 |
20050075662 | Pedersen et al. | Apr 2005 | A1 |
20050075712 | Biancucci et al. | Apr 2005 | A1 |
20050075717 | Nguyen et al. | Apr 2005 | A1 |
20050075719 | Bergheim | Apr 2005 | A1 |
20050075724 | Svanidze et al. | Apr 2005 | A1 |
20050075730 | Myers et al. | Apr 2005 | A1 |
20050075731 | Artof et al. | Apr 2005 | A1 |
20050085841 | Eversull et al. | Apr 2005 | A1 |
20050085842 | Eversull et al. | Apr 2005 | A1 |
20050085843 | Opolski et al. | Apr 2005 | A1 |
20050085890 | Rasmussen et al. | Apr 2005 | A1 |
20050090846 | Pedersen et al. | Apr 2005 | A1 |
20050090890 | Wu et al. | Apr 2005 | A1 |
20050096692 | Linder et al. | May 2005 | A1 |
20050096734 | Majercak et al. | May 2005 | A1 |
20050096735 | Hojeibane et al. | May 2005 | A1 |
20050096736 | Osse et al. | May 2005 | A1 |
20050096738 | Cali et al. | May 2005 | A1 |
20050100580 | Osborne et al. | May 2005 | A1 |
20050107822 | WasDyke | May 2005 | A1 |
20050113910 | Paniagua et al. | May 2005 | A1 |
20050131438 | Cohn | Jun 2005 | A1 |
20050137683 | Hezi-Yamit et al. | Jun 2005 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20050137687 | Salahieh et al. | Jun 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137689 | Salahieh et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh et al. | Jun 2005 | A1 |
20050137692 | Haug et al. | Jun 2005 | A1 |
20050137693 | Haug et al. | Jun 2005 | A1 |
20050137694 | Haug et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050137696 | Salahieh et al. | Jun 2005 | A1 |
20050137697 | Salahieh et al. | Jun 2005 | A1 |
20050137698 | Salahieh et al. | Jun 2005 | A1 |
20050137699 | Salahieh et al. | Jun 2005 | A1 |
20050137701 | Salahieh et al. | Jun 2005 | A1 |
20050137702 | Haug et al. | Jun 2005 | A1 |
20050138689 | Aukerman | Jun 2005 | A1 |
20050143807 | Pavcnik et al. | Jun 2005 | A1 |
20050143809 | Salahieh et al. | Jun 2005 | A1 |
20050149159 | Andreas et al. | Jul 2005 | A1 |
20050165352 | Henry et al. | Jul 2005 | A1 |
20050165477 | Anduiza et al. | Jul 2005 | A1 |
20050165479 | Drews et al. | Jul 2005 | A1 |
20050182486 | Gabbay | Aug 2005 | A1 |
20050197694 | Pai et al. | Sep 2005 | A1 |
20050197695 | Stacchino et al. | Sep 2005 | A1 |
20050203549 | Realyvasquez | Sep 2005 | A1 |
20050203614 | Forster et al. | Sep 2005 | A1 |
20050203615 | Forster et al. | Sep 2005 | A1 |
20050203616 | Cribier | Sep 2005 | A1 |
20050203617 | Forster et al. | Sep 2005 | A1 |
20050203618 | Sharkawy et al. | Sep 2005 | A1 |
20050203818 | Rotman et al. | Sep 2005 | A9 |
20050209580 | Freyman | Sep 2005 | A1 |
20050228472 | Case et al. | Oct 2005 | A1 |
20050228495 | Macoviak | Oct 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050240262 | White | Oct 2005 | A1 |
20050251250 | Verhoeven et al. | Nov 2005 | A1 |
20050251251 | Cribier | Nov 2005 | A1 |
20050261759 | Lambrecht et al. | Nov 2005 | A1 |
20050267560 | Bates | Dec 2005 | A1 |
20050283231 | Haug et al. | Dec 2005 | A1 |
20050283962 | Boudjemline | Dec 2005 | A1 |
20060004439 | Spenser et al. | Jan 2006 | A1 |
20060004442 | Spenser et al. | Jan 2006 | A1 |
20060015168 | Gunderson | Jan 2006 | A1 |
20060025854 | Lashinski et al. | Feb 2006 | A1 |
20060025855 | Lashinski et al. | Feb 2006 | A1 |
20060025857 | Bergheim et al. | Feb 2006 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060058889 | Case | Mar 2006 | A1 |
20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
20060155312 | Levine et al. | Jul 2006 | A1 |
20060161249 | Realyvasquez et al. | Jul 2006 | A1 |
20060173524 | Salahieh et al. | Aug 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060195184 | Lane et al. | Aug 2006 | A1 |
20060195185 | Lane et al. | Aug 2006 | A1 |
20060253191 | Salahieh et al. | Nov 2006 | A1 |
20060259134 | Schwammenthal et al. | Nov 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20060265056 | Nguyen et al. | Nov 2006 | A1 |
20060271166 | Thill et al. | Nov 2006 | A1 |
20060271172 | Tehrani | Nov 2006 | A1 |
20060287668 | Fawzi et al. | Dec 2006 | A1 |
20060287717 | Rowe et al. | Dec 2006 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070010877 | Salahieh et al. | Jan 2007 | A1 |
20070016286 | Herrmann et al. | Jan 2007 | A1 |
20070018214 | Ahn et al. | Jan 2007 | A1 |
20070027535 | Purdy et al. | Feb 2007 | A1 |
20070055340 | Pryor | Mar 2007 | A1 |
20070061008 | Salahieh et al. | Mar 2007 | A1 |
20070112355 | Salahieh et al. | May 2007 | A1 |
20070118214 | Salahieh et al. | May 2007 | A1 |
20070129795 | Hill et al. | Jun 2007 | A1 |
20070162107 | Haug et al. | Jul 2007 | A1 |
20070173918 | Dreher et al. | Jul 2007 | A1 |
20070203503 | Salahieh et al. | Aug 2007 | A1 |
20070244552 | Salahieh et al. | Oct 2007 | A1 |
20070282436 | Pinchuk | Dec 2007 | A1 |
20070288089 | Gurskis et al. | Dec 2007 | A1 |
20080009940 | Cribier | Jan 2008 | A1 |
20080033541 | Gelbart et al. | Feb 2008 | A1 |
20080033543 | Gurskis et al. | Feb 2008 | A1 |
20080071363 | Tuval et al. | Mar 2008 | A1 |
20080082165 | Wilson et al. | Apr 2008 | A1 |
20080125859 | Salahieh et al. | May 2008 | A1 |
20080188928 | Salahieh et al. | Aug 2008 | A1 |
20080208328 | Antocci et al. | Aug 2008 | A1 |
20080208332 | Lamphere et al. | Aug 2008 | A1 |
20080221672 | Lamphere et al. | Sep 2008 | A1 |
20080234814 | Salahieh et al. | Sep 2008 | A1 |
20080255661 | Straubinger et al. | Oct 2008 | A1 |
20080269878 | Iobbi | Oct 2008 | A1 |
20080275540 | Wen | Nov 2008 | A1 |
20080288054 | Pulnev et al. | Nov 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090030512 | Thielen et al. | Jan 2009 | A1 |
20090054969 | Salahieh et al. | Feb 2009 | A1 |
20090076598 | Salahieh et al. | Mar 2009 | A1 |
20090093877 | Keidar et al. | Apr 2009 | A1 |
20090171456 | Kveen et al. | Jul 2009 | A1 |
20090216312 | Straubinger et al. | Aug 2009 | A1 |
20090222076 | Figulla et al. | Sep 2009 | A1 |
20090240320 | Tuval et al. | Sep 2009 | A1 |
20090264759 | Byrd | Oct 2009 | A1 |
20090264997 | Salahieh et al. | Oct 2009 | A1 |
20090299462 | Fawzi et al. | Dec 2009 | A1 |
20100023120 | Holecek et al. | Jan 2010 | A1 |
20100036479 | Hill et al. | Feb 2010 | A1 |
20100036484 | Hariton et al. | Feb 2010 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100082089 | Quadri et al. | Apr 2010 | A1 |
20100082094 | Quadri et al. | Apr 2010 | A1 |
20100094392 | Nguyen et al. | Apr 2010 | A1 |
20100094399 | Dorn et al. | Apr 2010 | A1 |
20100100176 | Elizondo et al. | Apr 2010 | A1 |
20100121434 | Paul et al. | May 2010 | A1 |
20100131054 | Tuval et al. | May 2010 | A1 |
20100137979 | Tuval et al. | Jun 2010 | A1 |
20100161045 | Righini | Jun 2010 | A1 |
20100168844 | Toomes et al. | Jul 2010 | A1 |
20100185275 | Richter et al. | Jul 2010 | A1 |
20100191320 | Straubinger et al. | Jul 2010 | A1 |
20100191326 | Alkhatib | Jul 2010 | A1 |
20100191327 | Lane et al. | Jul 2010 | A1 |
20100219092 | Salahieh et al. | Sep 2010 | A1 |
20100249894 | Oba et al. | Sep 2010 | A1 |
20100249908 | Chau et al. | Sep 2010 | A1 |
20100249915 | Zhang | Sep 2010 | A1 |
20100249916 | Zhang | Sep 2010 | A1 |
20100249917 | Zhang | Sep 2010 | A1 |
20100249918 | Zhang | Sep 2010 | A1 |
20100256752 | Forster et al. | Oct 2010 | A1 |
20100262231 | Tuval et al. | Oct 2010 | A1 |
20100280495 | Paul et al. | Nov 2010 | A1 |
20100298931 | Quadri et al. | Nov 2010 | A1 |
20110000073 | O'Fallon et al. | Jan 2011 | A1 |
20110098802 | Braido et al. | Apr 2011 | A1 |
20110125258 | Centola | May 2011 | A1 |
20110166648 | Robin et al. | Jul 2011 | A1 |
20110172765 | Nguyen et al. | Jul 2011 | A1 |
20110213460 | Lashinski et al. | Sep 2011 | A1 |
20110218619 | Benichou et al. | Sep 2011 | A1 |
20110224781 | White | Sep 2011 | A1 |
20110230956 | White | Sep 2011 | A1 |
20110245918 | White | Oct 2011 | A1 |
20110257735 | Salahieh et al. | Oct 2011 | A1 |
20110264196 | Savage et al. | Oct 2011 | A1 |
20110276128 | Cao et al. | Nov 2011 | A1 |
20110276129 | Salahieh et al. | Nov 2011 | A1 |
20110288634 | Tuval et al. | Nov 2011 | A1 |
20110295363 | Girard et al. | Dec 2011 | A1 |
20110319991 | Hariton et al. | Dec 2011 | A1 |
20120016469 | Salahieh et al. | Jan 2012 | A1 |
20120016471 | Salahieh et al. | Jan 2012 | A1 |
20120022629 | Perera et al. | Jan 2012 | A1 |
20120022642 | Haug et al. | Jan 2012 | A1 |
20120029627 | Salahieh et al. | Feb 2012 | A1 |
20120041549 | Salahieh et al. | Feb 2012 | A1 |
20120041550 | Salahieh et al. | Feb 2012 | A1 |
20120046740 | Paul et al. | Feb 2012 | A1 |
20120053683 | Salahieh et al. | Mar 2012 | A1 |
20120059454 | Millwee et al. | Mar 2012 | A1 |
20120078356 | Fish et al. | Mar 2012 | A1 |
20120078357 | Conklin | Mar 2012 | A1 |
20120089224 | Haug et al. | Apr 2012 | A1 |
20120095549 | Forster et al. | Apr 2012 | A1 |
20120101567 | Jansen | Apr 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120132547 | Salahieh et al. | May 2012 | A1 |
20120136432 | Forster et al. | May 2012 | A1 |
20120143316 | Seguin et al. | Jun 2012 | A1 |
20120179244 | Schankereli et al. | Jul 2012 | A1 |
20120185039 | Tuval et al. | Jul 2012 | A1 |
20120197379 | Laske et al. | Aug 2012 | A1 |
20120226348 | Lane et al. | Sep 2012 | A1 |
20120232459 | Dann et al. | Sep 2012 | A1 |
20120245706 | Alavi et al. | Sep 2012 | A1 |
20120259409 | Nguyen et al. | Oct 2012 | A1 |
20120277850 | Bertini | Nov 2012 | A1 |
20120303113 | Benichou et al. | Nov 2012 | A1 |
20120303116 | Gorman et al. | Nov 2012 | A1 |
20120330409 | Haug et al. | Dec 2012 | A1 |
20130013057 | Salahieh et al. | Jan 2013 | A1 |
20130018457 | Gregg et al. | Jan 2013 | A1 |
20130030520 | Lee et al. | Jan 2013 | A1 |
20130046373 | Cartledge et al. | Feb 2013 | A1 |
20130079867 | Hoffman et al. | Mar 2013 | A1 |
20130079869 | Straubinger et al. | Mar 2013 | A1 |
20130090729 | Gregg et al. | Apr 2013 | A1 |
20130096664 | Goetz et al. | Apr 2013 | A1 |
20130116778 | Gregg et al. | May 2013 | A1 |
20130123796 | Sutton et al. | May 2013 | A1 |
20130138207 | Quadri et al. | May 2013 | A1 |
20130158656 | Sutton et al. | Jun 2013 | A1 |
20130184813 | Quadri et al. | Jul 2013 | A1 |
20130190865 | Anderson | Jul 2013 | A1 |
20130304199 | Sutton et al. | Nov 2013 | A1 |
20140000112 | Braido et al. | Jan 2014 | A1 |
20140005772 | Edelman et al. | Jan 2014 | A1 |
20140018911 | Zhou et al. | Jan 2014 | A1 |
20140094904 | Salahieh et al. | Apr 2014 | A1 |
20140114405 | Paul et al. | Apr 2014 | A1 |
20140114406 | Salahieh et al. | Apr 2014 | A1 |
20140121766 | Salahieh et al. | May 2014 | A1 |
20140135912 | Salahieh et al. | May 2014 | A1 |
20140172077 | Bruchman et al. | Jun 2014 | A1 |
20140243966 | Garde et al. | Aug 2014 | A1 |
20140243967 | Salahieh et al. | Aug 2014 | A1 |
20140277417 | Schraut et al. | Sep 2014 | A1 |
20140277423 | Alkhatib et al. | Sep 2014 | A1 |
20140350668 | Delaloye et al. | Nov 2014 | A1 |
20150005863 | Para | Jan 2015 | A1 |
20150012085 | Salahieh et al. | Jan 2015 | A1 |
20150073540 | Salahieh et al. | Mar 2015 | A1 |
20150073541 | Salahieh et al. | Mar 2015 | A1 |
20150127094 | Salahieh et al. | May 2015 | A1 |
20150142104 | Braido | May 2015 | A1 |
20150157455 | Hoang et al. | Jun 2015 | A1 |
20150320552 | Letac et al. | Nov 2015 | A1 |
20150320556 | Levi et al. | Nov 2015 | A1 |
20150327995 | Morin et al. | Nov 2015 | A1 |
20160045307 | Yohanan et al. | Feb 2016 | A1 |
20160199184 | Ma et al. | Jul 2016 | A1 |
20160213467 | Backus et al. | Jul 2016 | A1 |
20160220365 | Backus et al. | Aug 2016 | A1 |
20160256270 | Folan et al. | Sep 2016 | A1 |
20170049566 | Zeng et al. | Feb 2017 | A1 |
20170304049 | Hayes | Oct 2017 | A1 |
20170333183 | Backus | Nov 2017 | A1 |
20180353293 | Colavito | Dec 2018 | A1 |
20190110893 | Haarer | Apr 2019 | A1 |
Number | Date | Country |
---|---|---|
2002329324 | Jul 2007 | AU |
1338951 | Mar 2002 | CN |
19532846 | Mar 1997 | DE |
19546692 | Jun 1997 | DE |
19857887 | Jul 2000 | DE |
19907646 | Aug 2000 | DE |
10049812 | Apr 2002 | DE |
10049813 | Apr 2002 | DE |
10049814 | Apr 2002 | DE |
10049815 | Apr 2002 | DE |
0103546 | May 1988 | EP |
0144167 | Nov 1989 | EP |
579523 | Jan 1994 | EP |
0409929 | Apr 1997 | EP |
0850607 | Jul 1998 | EP |
0597967 | Dec 1999 | EP |
1000590 | May 2000 | EP |
1057459 | Dec 2000 | EP |
1057460 | Dec 2000 | EP |
1078610 | Feb 2001 | EP |
1088529 | Apr 2001 | EP |
0937439 | Sep 2003 | EP |
1340473 | Sep 2003 | EP |
1356793 | Mar 2004 | EP |
1042045 | May 2004 | EP |
0819013 | Jun 2004 | EP |
1430853 | Jun 2004 | EP |
1435879 | Jul 2004 | EP |
1439800 | Jul 2004 | EP |
1469797 | Oct 2004 | EP |
1472996 | Nov 2004 | EP |
1229864 | Apr 2005 | EP |
1059894 | Jul 2005 | EP |
1551274 | Jul 2005 | EP |
1551336 | Jul 2005 | EP |
1562515 | Aug 2005 | EP |
1570809 | Sep 2005 | EP |
1576937 | Sep 2005 | EP |
1582178 | Oct 2005 | EP |
1582179 | Oct 2005 | EP |
1589902 | Nov 2005 | EP |
1600121 | Nov 2005 | EP |
1156757 | Dec 2005 | EP |
1616531 | Jan 2006 | EP |
1605871 | Jul 2008 | EP |
2119417 | Nov 2009 | EP |
2749254 | Jun 2015 | EP |
2898858 | Jul 2015 | EP |
2926766 | Oct 2015 | EP |
2788217 | Jul 2000 | FR |
2056023 | Mar 1981 | GB |
2398245 | Aug 2004 | GB |
2006333940 | Dec 2006 | JP |
2007516055 | Jun 2007 | JP |
2010540079 | Dec 2010 | JP |
2014530724 | Nov 2014 | JP |
2014531292 | Nov 2014 | JP |
2015518775 | Jul 2015 | JP |
1271508 | Nov 1986 | SU |
1371700 | Feb 1988 | SU |
9117720 | Nov 1991 | WO |
9217118 | Oct 1992 | WO |
9301768 | Feb 1993 | WO |
9315693 | Aug 1993 | WO |
9504556 | Feb 1995 | WO |
9529640 | Nov 1995 | WO |
9614032 | May 1996 | WO |
9624306 | Aug 1996 | WO |
9640012 | Dec 1996 | WO |
9748350 | Dec 1997 | WO |
9829057 | Jul 1998 | WO |
9836790 | Aug 1998 | WO |
9850103 | Nov 1998 | WO |
9855047 | Dec 1998 | WO |
9857599 | Dec 1998 | WO |
9933414 | Jul 1999 | WO |
9940964 | Aug 1999 | WO |
9944542 | Sep 1999 | WO |
9947075 | Sep 1999 | WO |
9951165 | Oct 1999 | WO |
0009059 | Feb 2000 | WO |
2000009059 | Feb 2000 | WO |
0041652 | Jul 2000 | WO |
0044308 | Aug 2000 | WO |
0044311 | Aug 2000 | WO |
0044313 | Aug 2000 | WO |
0045874 | Aug 2000 | WO |
0047139 | Aug 2000 | WO |
0049970 | Aug 2000 | WO |
0067661 | Nov 2000 | WO |
0105331 | Jan 2001 | WO |
0106958 | Feb 2001 | WO |
0106959 | Feb 2001 | WO |
0108596 | Feb 2001 | WO |
0110320 | Feb 2001 | WO |
0110343 | Feb 2001 | WO |
0135870 | May 2001 | WO |
0149213 | Jul 2001 | WO |
0154624 | Aug 2001 | WO |
0154625 | Aug 2001 | WO |
0162189 | Aug 2001 | WO |
2001054625 | Aug 2001 | WO |
0164137 | Sep 2001 | WO |
0176510 | Oct 2001 | WO |
0197715 | Dec 2001 | WO |
0236048 | May 2002 | WO |
0241789 | May 2002 | WO |
0243620 | Jun 2002 | WO |
0247575 | Jun 2002 | WO |
02056955 | Jul 2002 | WO |
02069842 | Sep 2002 | WO |
02100297 | Dec 2002 | WO |
03003943 | Jan 2003 | WO |
03003949 | Jan 2003 | WO |
03011195 | Feb 2003 | WO |
03015851 | Feb 2003 | WO |
03028592 | Apr 2003 | WO |
03030776 | Apr 2003 | WO |
03032869 | Apr 2003 | WO |
03037222 | May 2003 | WO |
03037227 | May 2003 | WO |
03047468 | Jun 2003 | WO |
03047648 | Jun 2003 | WO |
03088873 | Oct 2003 | WO |
03094793 | Nov 2003 | WO |
03094797 | Nov 2003 | WO |
03096932 | Nov 2003 | WO |
2004006803 | Jan 2004 | WO |
2004006804 | Jan 2004 | WO |
2004014256 | Feb 2004 | WO |
2004019817 | Mar 2004 | WO |
2004021922 | Mar 2004 | WO |
2004023980 | Mar 2004 | WO |
2004019811 | Apr 2004 | WO |
2004026117 | Apr 2004 | WO |
2004041126 | May 2004 | WO |
2004043293 | May 2004 | WO |
2004047681 | Jun 2004 | WO |
2004058106 | Aug 2004 | WO |
2004066876 | Aug 2004 | WO |
2004082536 | Sep 2004 | WO |
2004089250 | Oct 2004 | WO |
2004089253 | Oct 2004 | WO |
2004093728 | Nov 2004 | WO |
2004105651 | Dec 2004 | WO |
2005002466 | Jan 2005 | WO |
2005004753 | Jan 2005 | WO |
2005009285 | Feb 2005 | WO |
2005011534 | Feb 2005 | WO |
2005011535 | Feb 2005 | WO |
2005023155 | Mar 2005 | WO |
2005027790 | Mar 2005 | WO |
2005046528 | May 2005 | WO |
2005046529 | May 2005 | WO |
2005048883 | Jun 2005 | WO |
2005065585 | Jul 2005 | WO |
2005084595 | Sep 2005 | WO |
2005087140 | Sep 2005 | WO |
2005096993 | Oct 2005 | WO |
2006005015 | Jan 2006 | WO |
2006009690 | Jan 2006 | WO |
2006027499 | Mar 2006 | WO |
2005062980 | May 2006 | WO |
2006127412 | Nov 2006 | WO |
2006138391 | Dec 2006 | WO |
2007033093 | Mar 2007 | WO |
2007035471 | Mar 2007 | WO |
2005102015 | Apr 2007 | WO |
2007044285 | Apr 2007 | WO |
2007058847 | May 2007 | WO |
2007092354 | Aug 2007 | WO |
2007097983 | Aug 2007 | WO |
2007053243 | Sep 2007 | WO |
2009042196 | Apr 2009 | WO |
2010017537 | Feb 2010 | WO |
2010042950 | Apr 2010 | WO |
2010098857 | Sep 2010 | WO |
2012116368 | Aug 2012 | WO |
2012162228 | Nov 2012 | WO |
2013009975 | Jan 2013 | WO |
2013012801 | Jan 2013 | WO |
2013028387 | Feb 2013 | WO |
2013070896 | May 2013 | WO |
2013074671 | May 2013 | WO |
2013096545 | Jun 2013 | WO |
2013184895 | Dec 2013 | WO |
2014008207 | Jan 2014 | WO |
2014140230 | Sep 2014 | WO |
2014203106 | Dec 2014 | WO |
2015085218 | Jun 2015 | WO |
2016126511 | Aug 2016 | WO |
2016126524 | Aug 2016 | WO |
2017027289 | Feb 2017 | WO |
Entry |
---|
US 8,062,356 B2, 11/2011, Salahieh et al. (withdrawn) |
US 8,062,357 B2, 11/2011, Salahieh et al. (withdrawn) |
US 8,075,614 B2, 12/2011, Salahieh et al. (withdrawn) |
US 8,133,271 B2, 03/2012, Salahieh et al. (withdrawn) |
US 8,211,170 B2, 07/2012, Paul et al. (withdrawn) |
Knudsen et al., “Catheter-implanted prosthetic heart valves.” Int'l J. of Art. Organs, 16(5): 253-262, May 1993. |
Kort et al, “Minimally Invasive Aortic Valve Replacement: Echocardiographic and Clinical Results ”Am Heart J., 142(3): 476-481, Sep. 2001. |
Lawrence et al., “Percutaneous Endovascular Graft: Experimental Evaluation,” Radiology, 163(2): 357-60 (May 1987). |
Levi et al., “Future of Interventional Cardiology in Pediactrics.” Current Opinion in Cardiol., 18:79-90 (2003). |
Levy, “Mycobacterium Chelonei Infection of Porcine Heart Valves.” The New England Journal of Medicine, Washington DC, 297(12), Sep. 22, 1977. |
Love et al., “The Autogenous Tissue Heart Valve: Current Status.” Journal of Cardiac Surgery, 6(4): 499-507, Mar. 1991. |
Lutter et al., “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation.” J. of Thoracic and Cardio. Surg., 123(4): 768-776, Apr. 2002. |
Magovern et al., “Twenty-five-Year Review of the Magovern-Cromie Sutureless Aortic Valve.” Ann. Thorac. Surg., 48:533-4 (1989). |
Maraj et al., Evaluation of Hemolysis in Patients with Prosthetic Heart Valves, Clin. Cardiol. 21, 387-392 (1998). |
McKay et al., “The Mansfield Scientific Aortic Valvuloplasty Registry: Overview of Acute Hemodynamic Results and Procedural Complications.” J. Am. Coll. Cardiol. 17(2): 485-91 (Feb. 1991). |
Mirich et al., “Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study.” Radiology, 170 1033-1037(1989). |
Moazami et al., “Transluminal Aortic Valve Placement: A Feasibility Study With a Newly Designed Collapsiable Aortic Valve,” ASAIO J. vol. 42:5, pp. M383-M385 (Sep./Oct. 1996). |
Moulopoulos et al., “Catheter-Mounted Aortic Valves.” Annals of Thoracic Surg., 11 (5): 423-430, May 1971. |
Paniagua et al., “Heart Watch.” Texas Heart Institute. Edition: 8 pages, Spring, 2004. |
Paniagua et al., “Percutaneous Heart Valve in the Chronic in Vitro Testing Model.” Circulation, 106: e51-e52, Sep. 17, 2002. |
Parodi et al., “Transfemoral Intraluminal Graft Implantation for Abdominal Aortic Aneurysms.” Ann. Vase. Surg., 5 (6):491-9 (1991). |
Pavcnik et al., “Percutaneous Bioprosthetic Venous Valve: A Long-term Study in Sheep.” J. of Vascular Surg., 35(3): 598-603, Mar. 2002. |
Pavcnik et al., “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement.” Radiology 183:151-54 (1992). |
Pavcnik, et al., “Aortic and venous valve for percutaneous insertion,” Min. Invas. Ther. & Allied Technol. 9(3/4) 287-292 (2000). |
Phillips et al., “A Temporary Catheter-Tip Aortic Valve: Hemodynamic Effects on Experimental Acute Aortic Insufficiency.” Annals of Thoracic Surg., 21(2): 134-136, Feb. 1976. |
Printz, et al., “Let the Blood Circulate.” Sulzer Tech. Rev. 4/99. |
U.S. Appl. No. 60/553,945 to White. |
Raillat et al., “Treatment of Iliac Artery Stenosis with the Wallstent Endoprosthesis.” AJR 154(3):613-6 (Mar. 1990). |
Remadi et al., “Preliminary results of 130 aortic valve replacements with a new mechanical bileaflet prosthesis: the Edwards MIRA valve” Interactive Cardiovasc. and Thorac. Surg. 2, 80-83 (2003). |
Rosch et al., “Gianturco-Rosch Expandable Z-Stents in the Treatment of Superior Vena Cava Syndrome.” Cardiovasc. Intervent. Radiol. 15: 319-327 (1992). |
Schurink et al.,. “Stent Attachment Site-related Endoleakage after Stent Graft Treatment: An in vitro study of the affects of graft size, stent type, and atherosclerotic wall changes” J. Vasc. Surg., 30(4):658-67 (Oct. 1999). |
Deminars in Interventaional Cardiology, ed. P.W. Surruys, vol. 5 (200). |
Sochman et al., “Percutaneous Transcatheter Aortic Disc Valve Prosthesis Implantation: A Feasibility Study.” Cardiovasc. Intervent Radiol., 23: 384-388, Sep. 2000. |
Southern Lights Biomaterials Homepage, http://www.slv.co.nz/, Jan. 7, 2011. |
Stanley et al., “Evaluation of Patient Selection Guidelines for Endoluminal AAA Repair With the Zenith Stent Graft The Australasian Experience ” J. Endovasc. Ther. 8:457-464 (2001). |
Thompson et al., “Endoluminal stent grafting of the thoracic aorta: Initial experience with the Gore Excluder,” Journal of Vascular Surgery, 1163-70 (Jun. 2002). |
Steinhoff et al., “Tissue Engineering of Pulmonary Heart Valves on Allogenic Acellular Matrix Conduits.” Circulation, 102 [suppl. III]: III-50-III-55 (2000). |
Stuart, “In Heart Valves, A Brave, New Non-Surgical World.” Start-Up. Feb. 9-17, 2004. |
Supplemental Search Report from EP Patent Office, EP Application No. 04815634.3, dated Aug. 19, 2011. |
Supplemental Search Report from EP Patent Office, EP Application No. 05758878.2, dated Oct. 24, 2011. |
Textbook of Interventional Cardiology, 2d Ed., Chapter 75: Percutaneous Expandable Prosthetic Valves (1994). |
Stassano, “Mid-term Results of the Valve on Valve Technique for Bioprosthetic failure.” European journal of Ccardiothoracic Surgery:vol. 18, 453-457, Oct. 2000. |
Topol, “Percutaneous Expandable Prosthetic Valves.” Textbook of Interventional Cardiology, W.B. Saunders Company, 2: 1268-1276, 1994. |
Vahanian et al., “Percutaneous Approaches to Valvular Disease.” Circulation, 109: 1572-1579, Apr. 6, 2004. |
Van Herwerden et al., “Percutaneous Valve Implantation: Back to the Future?” Euro. Heart J., 23(18): 1415-1416, Sep. 2002. |
VentureBeatProfiles, Claudio Argento, Jan. 7, 2010, http://venturebeatprofiles.com/person/profile/claudio-argento. |
Vossoughi et al., Stent Graft Update (2000)—Kononov, Volodos, and Parodi and Palmaz Stents; Hemobahn Stent Graft. |
White et al., “Endoleak as a Complication of Endoluminal Grafting of Abdominal Aortic Aneurysms: Classification, Incidence, Diagnosis, and Management.” J. Endovac. Surg., 4:152-168 (1997). |
Yoshioka et al., “Self-Expanding Endovascular Graft: An Experimental Study in Dogs.” AJR 151: 673-76 (Oct. 1988). |
USPTO Case IPR2017-01293, U.S. Pat. No. 8,992,608 B, Oct. 13, 2017. |
Zhou et al., “Self-expandable Valved Stent of Large Size: Off-Bypass Implantation in Pulmonary Position.” Eur. J. Cardiothorac, 24: 212-216, Aug. 2003. |
Gore Excluder Instructions for Use (2002). |
USPTO Case IPR2016-___, U.S. Pat. No. 8,992,608 “Petition for Interpartes Review of U.S. Pat. No. 8,992,608” Oct. 12, 2016. |
USPTO Case IPR 2017-0006, U.S. Pat. No. 8,992,608 B2, “Final Written Decision” dated Mar. 23, 2018. |
Fluency Vascular Stent Graft Instructions for Use (2003). |
Cribier et al., “Percutaneous Transluminal Valvuloplasty of Acquired Aortic Stenosis in Elderly Patients: An Alternative to Valve Replacement?” The Lancet, 63-7 (Jan. 11, 1986). |
Supplemental Search Report from EP Patent Office, EP Application No. 04813777.2, dated Aug. 19, 2011. |
Laborde et al., “Percutaneous Implantation of the Corevalve Aortic Valve Prosthesis for Patients Presenting High Risk for Surgical Valve Replacement.” EuroIntervention: 472-474, Feb. 2006. |
“A Matter of Size.” Triennial Review of the National Nanotechnology Initiative, The National Academies Press, Washington DC, v-13, http://www.nap.edu/catalog/11752/a-matter-of-size-triennial-review-of-the-national-nanotechnology, 2006. |
“Heart Valve Materials—Bovine (cow).” Equine & Porcine Pericardium, Maverick Biosciences Pty. Lt, http://maverickbio.com/biological-medical-device-materials.php?htm. 2009. |
“Pericardial Heart Valves.” Edwards Lifesciences, Cardiovascular Surgery FAQ, http://www.edwards.com/products/cardiovascularsurgeryfaq.htm, Nov. 14, 2010. |
Allen et al., “What are the characteristics of the ideal endovascular graft for abdominal aortic aneurysm exclusion?” J. Endovasc. Surg., 4(2):195-202 (May 1997). |
Andersen et al. “Transluminal catheter implantation of a new expandable artificial cardiac valve (the stent—valve) in the aorta and the beating heart of closed chest pigs (Abstract).” Eur. Heart J., 11 (Suppl.): 224a (1990). |
Andersen et al., “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J., 13:704-708, May 1992. |
Atwood et al., “Insertion of Heart Valves by Catheterization.” Project Supervised by Prof. S. Muftu of Northeastern University 2001-2002: 36-40, May 30, 2002. |
Atwood et al., “Insertion of Heart Valves by Catheterization.” The Capstone Design Course Report. MIME 1501-1502 Technical Design Report. Northeastern University, pp. 1-93, Nov. 5, 2007. |
Bailey, “Percutaneous Expandable Prosthetic Valves, Textbook of Interventional Cardiology.” vol. 2,2d ed. Eric J. Topol, W.B. Saunders Co. (1994). |
Blum et al., “Endoluminal Stent-Grafts for Intrarenal Abdominal Aortic Aneurysms.” New Engl. J. Med., 336:13-20 (1997). |
Bodnar et al., “Replacement Cardiac Valves R Chapter 13: Extinct Cardiac Valve Prostheses.” Pergamon Publishing Corporation. New York, 307-322, 1991. |
Bonhoeffer et al., “Percutaneous Insertion of the Pulmonary Valve.” J. Am. Coll. Cardiol., 39:1664-9 (2002). |
Bonhoeffer et al., “Transcatheter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study.” Circulation, 102: 813-16 (2000). |
Bonhoeffer, et al., “Percutaneous replacement of pulmonary valve in a right ventricle to pulmonary-artery prosthetic conduit with valve dysfunction.” The Lancet, vol. 356, 1403-05 (Oct. 21, 2000). |
Boudjemline et al., “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study.” Med Sci. Monit., vol. 8, No. 4: BR113-116, Apr. 12, 2002. |
Boudjemline et al., “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs.” Euro. Heart J., 23: 1045-1049, Jul. 2002. |
Boudjemline et al., “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study.” Journal of the American College of Cardiology, vol. 43(6): 1082-1087, Mar. 17, 2004. |
Boudjemline et al., “Percutaneous Valve Insertion: A New Approach?” J. of Thoracic and Cardio. Surg, 125(3): 741-743, Mar. 2003. |
Boudjemline et al., “Steps Toward Percutaneous Aortic Valve Replacement.” Circulation, 105: 775-778, Feb. 12, 2002. |
Couper, “Surgical Aspects of Prosthetic Valve Selection,” Overview of Cardiac Surgery for the Cardiologist, Springer-Verlag New York, Inc., 131-145 (1994). |
Cribier et al., “Early Experience with Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients with Calcific Aortic Stenosis.” J. of Am. Coll. of Cardio, 43(4): 698-703, Feb. 18, 2004. |
Cribier et al., “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis First Human Case.” Percutaneous Valve Technologies, Inc., 16 pages, Apr. 16, 2002. |
Cribier et al., “Percutaneous Transcatheter Implementation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis First Human Case Description.” Circulation, 106: 3006-3008, Dec. 10, 2002. |
Cribier et al., “Trans-Cathether Implantation of Balloon-Expandable Prosthetic Heart Valves: Early Results in an Animal Model.” Circulation [suppl. II] 104(17) II-552 (Oct. 23, 2001). |
Cunanan et al., “Tissue Characterization and Calcification Potential of Commercial Bioprosthetic Heart Valves.” Ann. Thorac. Surg., S4 17-421, May 15, 2001. |
Cunliffe et al., “Glutaraldehyde Inactivation of Exotic Animal Viruses in Swine Heart Tissue.” Applied and Environmental Microbiology, Greenport, New York, 37(5): 1044 1046, May 1979. |
Dake et al., “Transluminal Placement of Endovascular Stent-Grafts for the Treatment of Descending Thoracic Aortic Aneurysms.” New Engl. J. of Med., 331(26):1729-34 (1994). |
Dalby et al., “Non-Surgical Aortic Valve Replacement” Br. J. Cardiol., 10:450-2 (2003). |
Dhasmana, et al., “Factors Associated With Periprosthetic Leakage Following Primary Mitral Valve Replacement: With Special Consideration of Suture Technique.” Annals of Thorac. Surg. 35(2), 170-8 (Feb. 1983). |
Diethrich, AAA Stent Grafts: Current Developments, J. Invasive Cardiol. 13(5) (2001). |
Dolmatch et al., Stent Grafts: Current Clinical Practive (2000)—EVT Endograft and Talent Endoprosthesis. |
Dotter, “Transluminally-Placed Coilspring Endarterial Tube Grafts,” Investigative Radiology, pp. 329-332 (1969). |
Emery et al., “Replacement of the Aortic Valve in Patients Under 50 Years of Age: Long-Term Follow-Up of the St. Jude Medical Prosthesis.” Ann. Thorac. Surg., 75:1815-9 (2003). |
EP Search Report for EP Application No. 06824992.9, dated Aug. 10, 2011. |
Examiner's First Report on AU Patent Application No. 2011202667, dated May 17, 2012. |
Ferrari et al., “Percutaneous Transvascular Aortic Valve Replacement with Self-Expanding Stent-Valve Device.” Poster from the presentation given at SMIT 2000, 12th International Conference Sep. 5, 2000. |
Greenberg, “Abdominal Aortic Endografting: Fixation and Sealing.” J. Am. Coll. Surg. 194:1:S79-S87 (2002). |
Grossi, “Impact of Minimally Invasive Valvular Heart Surgery: A Case-Control Study.” Ann. Thorac. Surg., 71:807-10 (2001). |
Helmus, “Mechanical and Bioprosthetic Heart Valves in Biomaterials for Artificial Organs.” Woodhead Publishing Limited: 114-162, 2011. |
Hijazi, “Transcatheter Valve Replacement: A New Era of Percutaneous Cardiac Intervention Begins.” J. of Am. College of Cardio., 43(6): 1088-1089, Mar. 17, 2004. |
Hourihan et al., “Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks.” JACC, Boston, Massachusetts, 20(6): 1371-1377, Nov. 15, 1992. |
Huber et al., “Do Valved Stents Compromise Coronary Flow?” European Journal of Cardio-thoracic Surgery, vol. 25: 754-759, Jan. 23, 2004. |
Ing, “Stents: What's Available to the Pediatric Interventional Cardiologist?” Catheterization and Cardiovascular Interventions 57:274-386 (2002). |
Ionescu, et al., “Prevalence and Clinical Significance of Incidental Paraprosthetic Valvar Regurgitation: A prospective study using transesophageal echocardiography.” Heart, 89:1316-21 (2003). |
Kaiser, et al., “Surgery for Left Ventricle Outflow Obstruction: Aortic Valve Replacement and Myomectomy,” Overview of Cardiac Surgery for the Cardiologist. Springer-Verlag New York, Inc., 40-45 (1994). |
Kato et al., “Traumatic Thoracic Aortic Aneurysm: Treatment with Endovascular Stent-Grafts.” Radiol., 205: 657-662 (1997). |
Khonsari et al., “Cardiac Surgery: Safeguards and Pitfalls in Operative Technique.” 3d ed., 45-74 (2003). |
Carpentier-Edwards PERIMOUNT Bioprosthesis (2003). |
International Search Report and Written Opinion dated Oct. 22, 2018 for International Application No. PCT/US2018/044318. |
Invite to Pay Additional Fees and, where Applicable, Protest Fee, dated Nov. 14, 2016 for International Application No. PCT/US2016/045335. |
International Search Report and Written Opinion dated Feb. 2, 2017 for International Application No. PCT/US2016/045323. |
International Search Report and Written Opinion dated Aug. 16, 2017 for International Application No. PCT/US2017/033160. |
International Search Report and Written Opinion dated Apr. 21, 2016 for International Application No. PCT/US2016/014878. |
International Preliminary Report on Patentability and Written Opinion dated Aug. 10, 2017 for International Application No. PCT/US2016/014878. |
International Search Report and Written Opinion dated Jul. 17, 2017 for International Application No. PCT/US2017/029552. |
International Search Report and Written Opinion dated Jul. 12, 2016 for International Application PCT/US2016/014401. |
Number | Date | Country | |
---|---|---|---|
20200352708 A1 | Nov 2020 | US |
Number | Date | Country | |
---|---|---|---|
62846018 | May 2019 | US |